US20080125702A1 - Non-constant pressure infusion pump - Google Patents
Non-constant pressure infusion pump Download PDFInfo
- Publication number
- US20080125702A1 US20080125702A1 US12/021,967 US2196708A US2008125702A1 US 20080125702 A1 US20080125702 A1 US 20080125702A1 US 2196708 A US2196708 A US 2196708A US 2008125702 A1 US2008125702 A1 US 2008125702A1
- Authority
- US
- United States
- Prior art keywords
- reservoir
- infusate
- pressure
- valve
- flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14264—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with means for compensating influence from the environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M2005/14506—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons mechanically driven, e.g. spring or clockwork
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
- A61M2205/3372—Temperature compensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16877—Adjusting flow; Devices for setting a flow rate
- A61M5/16881—Regulating valves
Definitions
- the present invention relates to an implantable infusion pump, and in particular, to an infusion pump capable of effecting a precisely controlled (constant or variable) fluid flow delivery rate, independent of a constant reservoir pressure.
- Modern implantable infusion devices, or implantable pumps, for delivering an infusate commonly have a rigid housing that maintains a collapsible infusate reservoir.
- the housing includes a needle-penetrable septum that covers a reservoir inlet.
- a flow passage is provided between the reservoir and an exterior surface of the device. At the flow passage outlet, a flexible delivery catheter is provided.
- These devices are implanted at a selected location in a patient's body so that (i) the inlet septum is proximate to the patient's skin and (ii) a distal end of the catheter is positioned at a selected delivery site. Infusate can then be delivered to the infusion site by controlling the flow of such fluid from the device infusate reservoir into the delivery catheter. When the infusate reservoir becomes empty, the reservoir is refillable through the reservoir inlet by injecting a new supply of infusate through the apparatus' inlet septum. Due to the location of the device in relation to the skin of the patient, injection can be readily accomplished using a hypodermic needle (or cannula).
- Infusate is expelled from the reservoir to an infusion site by collapsing the reservoir.
- Some infusion pumps use an electrically powered mechanism to “actively” pump infusate from the infusate reservoir into the delivery catheter.
- active pumping devices include so-called peristaltic pumps (e.g., SynchroMed® implantable pump from Medtronic, Inc., Minneapolis, Minn.) and accumulator-type pumps (e.g., certain external infusion pumps from Minimed, hIc., Northridge, Calif. and Infusaid® implantable pump from Strato/Infusaid, Inc., Norwood, Mass.).
- peristaltic pumps e.g., SynchroMed® implantable pump from Medtronic, Inc., Minneapolis, Minn.
- accumulator-type pumps e.g., certain external infusion pumps from Minimed, hIc., Northridge, Calif. and Infusaid® implantable pump from Strato/Infusaid, Inc., Norwood, Mass.
- a passive pumping mechanism generally consists of a means of pressurizing the infusate reservoir and a means of restricting the fluid flow. All of these devices operate under the principle that the fluid flow rate (Q) is directly proportional to a pressure difference ( ⁇ P) between the infusate reservoir interior and the delivery site and inversely proportional to the total flow resistance provided by the fluid passage and delivery catheter (collectively (R)), wherein
- a practical pump must have a predictable flow rate (Q). To achieve this goal, conventional designs have strived to develop substantially constant pressure sources.
- the first means of developing such a “constant pressure source” includes using a two-phase fluid, or propellant, that is contained within the rigid housing and is further confined within a fluid-tight space adjacent to the infusate reservoir. Pumps constructed in this manner are called “gas-driven” pumps.
- the propellant is both a liquid and a vapor at patient physiological temperatures, e.g., 98.6° F., and theoretically exerts a positive, constant pressure over a full volume change of the reservoir, thus effecting the delivery of a constant flow of infusate.
- a portion of such vapor reverts to its liquid phase and thereby maintains a state of equilibrium between the fluid and gas states at a “vapor pressure,” which is a characteristic of the propellant.
- vapor pressure which is a characteristic of the propellant.
- Gas-driven infusion pumps typically provide an electrically efficient means to deliver a flow of infusate throughout a delivery cycle.
- infusion pumps depend upon a constant pressure source, wherein the output fluid flow rate is directly proportional to a propellant-reservoir pressure. If the propellant-reservoir pressure varies, then so will the fluid flow rate and the drug delivery rate.
- the propellant-reservoir pressure of conventional gas-driven infusion pumps are susceptible to changes in ambient temperature and pressure. This, in turn, makes the fluid flow rate such devices susceptible to changes in ambient temperature and pressure. Such changes in drug infusion rates are undesirable and, in certain situations, unacceptable.
- Circumstances readily exist where either ambient temperature or pressure can rapidly change a significant amount.
- the reservoir pressure of some conventional gas-driven pumps can change as much as 0.5 psi for each 1° F. change in body temperature.
- a fever of only 102.6° F. can result in a twenty-five percent (25%) increase in propellant-reservoir pressure and thus, a corresponding (or larger) increase in an fluid flow rate.
- changes in environmental temperature affect the infusate viscosity as well as the vapor pressure produced by the propellant, thereby further increasing the pump's susceptibility to temperature.
- the rigid housing of the conventional, gas-driven infusion pump provides an absolute constant-internal pressure (P R ) (at constant temperature) independent of external pressures.
- P R absolute constant-internal pressure
- P D ambient pressure
- some conventional gas-driven infusion devices have been provided with elevated reservoir pressures.
- the increased reservoir pressures are not intended to prevent variations in a constant pressure delivery but are intended to mitigate their effect.
- the effect on flow rate is effectively lessened if the total percentage of pressure change (relative to the reservoir pressure) can be reduced.
- These infusion devices possess undesirable attributes in that refilling operations are more difficult and the high-pressure vessels, which form the pump housing structures, must necessarily be stronger and are therefore more susceptible to manufacturing problems.
- a pressure regulator such as that disclosed in U.S. Pat. No. 4,299,220.
- the pressure regulator described therein which is positioned between the infusate reservoir and delivery catheter, uses a diaphragm valve to maintain a constant pressure differential (OP) across the fluid flow restrictor.
- OP constant pressure differential
- the pressure regulator may, depending upon device configuration, subject infusate solutions to high local shear stresses, which may alter the chemical or therapeutic properties of certain infusates.
- An object of the present invention is to provide an implantable infusion device with a non-constant reservoir pressure (over at least a portion of the flow cycle) that controls fluid flow across a fluid flow restrictor (with or without other fluid control elements) by dividing a greater dose cycle into a series of (smaller) unit dose cycles over which the reservoir pressure is substantially constant.
- Another object of the present invention is to provide an electrically efficient implantable infusion device, having a convenient pressure reservoir, that is capable of delivering a prescribed dosage of a fluid infusate independent of either a constant reservoir pressure, ambient temperature or pressure, changes in device performance, or infusate properties.
- Another objective of the present invention is to provide an implantable infusion device that is simpler in construction.
- the present invention is directed to a controlled-rate infusion device for implantation in a living body.
- the infusion device includes a collapsible infusate chamber, an energy source to collapse the chamber, and an outlet flow path extending between the chamber and a device outlet.
- the infusion device further includes at least one flow restrictor, a controller, at least one valve or variable flow restrictor to selectively alter a flow resistance of the outlet flow path, and at least one pressure sensing device.
- the pressure sensing device(s) are positioned relative to the outlet flow path as well as about the flow resistance (i.e., any combination of flow restrictors and/or valves).
- the controller is adapted to control an operation of the valve (or variable flow restrictor) based on measured value(s) obtained by the pressure sensing device(s).
- the present invention is directed to a controlled-rate infusion device for implantation in a living body.
- the infusion device includes a collapsible infusate chamber, an energy source to collapse the chamber, and an outlet flow path extending between the chamber and a device outlet.
- the infusion device further includes a controller, a valve (or variable flow restrictor) to selectively obstruct the outlet flow path, and one or more pressure sensing devices.
- the pressure sensing devices are positioned relative to the outlet flow path as well as about the flow resistance.
- the controller is adapted to assess whether output flow from the device is undesirably restricted based on measured values obtained from the pressure sensing devices.
- Another aspect of the present invention is directed to a method for controlling infusate output from an implantable-infusion device for a prescribed dose period.
- the device includes a collapsible infusate chamber, an energy source to collapse the chamber, and an outlet flow path extending between the chamber and a device outlet, and the outlet flow path includes a restrictor network, which includes an occlude the outlet flow path.
- the method includes the steps of: (i) dividing the prescribed dose period into a plurality of unit dose periods, wherein each unit dose period is defined by an open-close cycle of the valve; and (ii) modifying a duty cycle of the open-close cycle of the valve so as to maintain a prescribed output volume (i.e., a unit dose) for each unit dose period.
- Another aspect of the method for controlling infusate output from an implantable infusion device can include, independent of or in cooperation with other aspects of this method, measuring an infusate pressure differential across the restrictor network (or a portion thereof).
- the step of modifying the duty cycle is performed in accordance with a measured infusate pressure differential.
- Another aspect of the method for controlling infusate output from an implantable infusion device can include, independent of or in cooperation with other aspects of this method, actuating the valve so as to effect a change in an occluded state of the outlet flow path. During or proximate to such actuation, a transient pressure profile on one side of the valve is measured, thus enabling an assessment of the performance of the valve, fluid path, flow restrictor and any other elements of the flow control system or flow path.
- Another aspect of the method for controlling infusate output from an implantable infusion device can include, independent of or in cooperation with other aspects of this method, measuring an infusate temperature.
- the step of modifying the duty cycle is performed in accordance with a measured infusate temperature.
- an output flow rate of a controlled rate pump can be changed by “resetting,” or programming, such output flow rate.
- This resetting operation can be accomplished using non-invasive (e.g., magnetic switch, radio-frequency telemetry) or invasive methods (e.g., transcutaneous trocar).
- non-invasive e.g., magnetic switch, radio-frequency telemetry
- invasive methods e.g., transcutaneous trocar.
- the methods and devices described herein can be used to construct a programmable pump, the flow rate of which can be manually or automatically (responsive to a clock, sensor, or other data input) modified to any of various beneficial patterns.
- FIG. 1 schematically illustrates a conventional implantable infusion device for delivering an infusate at a prescribed rate incorporating a passive pumping mechanism
- FIG. 2A schematically illustrates an implantable infusion device in accordance with one embodiment of the present invention
- FIG. 2B schematically illustrates an implantable infusion device in accordance with another embodiment of the present invention
- FIG. 2C schematically illustrates an implantable infusion device in accordance with another embodiment of the present invention
- FIG. 3 illustrates an exemplary timing chart corresponding to valve control for regulating a delivery of infusate from an infusate reservoir of the implantable infusion device of either FIG. 2A , 2 B, or FIG. 2C ;
- FIG. 4 schematically illustrates an implantable infusion device in accordance with another embodiment of the present invention
- FIG. 5 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention.
- FIG. 6 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention.
- FIG. 7 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention.
- FIG. 8 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention.
- FIG. 9 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention.
- FIG. 10 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention.
- FIG. 11 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention.
- FIG. 1 illustrates a conventional, constant flow rate infusion device 10 .
- the device 10 is characterized by an infusate reservoir 12 that is required to store a prescribed volume of infusate, e.g., insulin, medicament, pain relieving drugs, etc.
- the infusate reservoir 12 is of sufficient volume so as to provide a supply of infusate (i.e., a prescribed dose (D)) over a flow period ( ⁇ ) at a (theoretically) constant flow rate.
- D prescribed dose
- ⁇ flow period
- the volume of the infusate reservoir 12 can be fixed at any prescribed volume to enable delivery of a precisely controlled volume of infusate from one day to more than three months.
- the infusate reservoir 12 can be refilled through a septum 14 .
- Infusate is pressurized and thereby driven from the infusate reservoir 12 by a drive source 16 .
- the physical nature of the drive source 16 can be a two-phase fluid, which is confined between the housing of the device 10 and a movable diaphragm structure 18 , a drive spring that forms the diaphragm structure 18 , or like mechanisms/structures that develop a substantially constant pressure.
- a flow restrictor 20 is positioned downstream from the infusate reservoir 12 to establish an output flow rate.
- the flow restrictor 20 can be constructed of any number of potential structures, for example, a plate having a groove formed therein, capillary tubing, an etched flow chip, or the like.
- a filter is preferably interpositioned between the infusate reservoir 12 and the restrictor 20 to prevent any bacteria present in the infusate reservoir 12 from being transferred into the body, and to a certain extent, to protect the restricted flow path defined by the restrictor 20 .
- Flow from the flow restrictor 20 is passed to a catheter 22 having its distal end positioned at a site for fluid delivery.
- Conventional implantable infusion devices can further include a bolus port structure 24 .
- the bolus port structure 24 whether integral with the device 10 or separate therefrom, provides direct fluid communication with the catheter 22 .
- the bolus port structure 24 is adapted to receive independently a hypodermic needle (or cannula). Fluid delivered to the bolus port structure 24 can be used to flush the downstream catheter 22 , deliver a prescribed dosage of medicament (possibly of a volume greater or at a rate greater than that otherwise capable to be delivered through the flow restriction 20 ), or perform troubleshooting or diagnostic procedures.
- the structure 24 can also allow extraction of fluid from the patient via the catheter 22 .
- FIG. 2A illustrates one embodiment of the present invention.
- an implantable infusion device has a infusate reservoir 12 connected between a septum 14 and a flow restrictor 20 .
- Infusate within the infusate reservoir 12 is pressurized and thereby driven through the flow restrictor 20 by the drive source 16 .
- the illustrated infusion device includes a first pressure sensing device 24 , to measure a pressure upstream of the flow restrictor 20 , and a second pressure sensing device 26 , to measure a pressure downstream of the flow restrictor 20 .
- Respective positions of the pressure sensing devices 24 and 26 relative to a flow path through the infusion device are not critical so long as the pressure sensing device 24 remains upstream of the flow restrictor 20 and the pressure sensing device 26 remains downstream of the flow restrictor 20 .
- the flow rate will be determined by a pressure differential ( ⁇ P) at the point of the pressure sensing devices 24 and 26
- ⁇ P pressure differential
- FIGS. 2A to 11 illustrate some of the possible configuration-combinations that includes: (i) one or more flow restrictors arranged in parallel, series, or combinations thereof, (ii) one or more valves, whereby these elements can affect an overall flow resistance; and (iii) one or more pressure sensors that are capable of determining a pressure difference across any portion of or all of the flow restrictors or valves.
- fixed or variable flow restrictors which includes mono-stable, bi-stable, or multi-stable valves that have the potential of occluding or partially occluding the possible flow paths.
- a valve 28 is positioned downstream of the flow restrictor 20 , and is preferably positioned downstream of the pressure sensing device 26 . Accordingly, the pressure sensing device 24 can be 24 can be positioned within or proximate to the infusate reservoir 12 , and the pressure sensing device 26 can be positioned subsequent to the valve 28 .
- a controller 30 (e.g., a microprocessor) is electrically connected to the pressure sensing device 24 , the pressure sensing device 26 , and the valve 28 .
- the controlled 30 functions to control fluid flow through the valve 28 based on respective outputs form pressure sensing devices 24 and 26 .
- a fluid flow rate across the flow restrictor 20 can be calculated from:
- An optional temperature sensing device 38 can also be coupled to the controller 30 . If provided, the controller 30 would function to control fluid flow through the valve 28 also in consideration of (or solely based on) an output from the temperature sensing device 38 .
- the controller 30 is adapted to relate changes in an infusate temperature to proportional changes in system pressure and/or to changes in the resistive value (R), the latter being caused by a change in fluid viscosity due to a change in infusate temperature. This ability of the controller 30 is managed by algorithm or look-up tables stored in memories 32 and/or 34 .
- a flow cycle of an infusion device is considered to extend through the delivery of the contents of the infusate reservoir 12 , i.e., from a refilling event until a subsequent refilling event.
- the quantity (S) of active pharmacological agents or other agents (individually or collectively “agent”) contained in the infusate reservoir 12 depends upon the fluid volume (V) of the infusate reservoir 12 and the concentration of the agent in the infusate stored therein:
- the duration of the flow cycle is referred to as the flow period ( ⁇ ). As is probable, the flow period will typically be between 1 and over three (3) months. It is related to the flow rate (Q) and the infusate reservoir volume (V) as follows:
- a prescribed (or desired) dose (D) delivered must be further calculated in accordance with the following:
- the devices of the present invention seek to provide the desired flow accuracy in spite of the fact that the pressure differential ( ⁇ P) and/or flow resistance (R) may not remain constant over the entire flow period ( ⁇ ). These devices do this by subdividing the flow period ( ⁇ ) into smaller unit dose periods (t i,j ) over which the flow parameters ( ⁇ P) and (R) are likely to remain constant and delivering the total dose (D) though a series of sequential unit dose periods (t i,j ).
- ⁇ P pressure differential
- R flow resistance
- a flow period ( ⁇ ) can be subdivided into any number (n) of prescribed dose periods (T i ), which may or may not be of equal duration.
- n may be any integer, preferably two or greater.
- the duration of the prescribed dose periods (T i ) may or may not be physician-alterable (i.e., to create a programmable pump) and/or patient-alterable (i.e., to create a programmable pump with patient-controllable elements) either before or during the flow period ( ⁇ ).
- a prescribed dose (D i ) is delivered. If all of these prescribed doses (D i ) are equal, then the equations describe a constant flow infusion device, possibly with improved flow accuracy such as, for example, illustrated in FIG. 2A . If these are multiple prescribed doses (D i ) of different magnitudes, then the equations describe a programmable pump operating with a complex continuous infusion pattern. The therapeutic value of theses complex infusion patterns is readily apparent to clinicians, and varies depending upon the agent, patient, and application.
- each of the prescribed dose periods (T i ) is further divided into any number (m i ) of unit dose periods (t i,j ).
- “m” may be any integer, one or greater.
- all of the unit dose periods (t i,j ) within a given prescribed dose period (T i ) are equal. This simplifies the calculations necessary for device operation; however, this is not a necessary condition.
- m may be any integer, one or greater.
- valve 28 During each unit dose period (t i,j ), the valve 28 will be actuated through one complete cycle, such that it is in one position (i.e., designated open) for a fraction of the unit dose period (t i,j ) and in a second position (i.e., designated closed) for the balance of the unit dose period (t i,j ).
- a first position i.e., designated open
- a second position i.e., designated closed
- the controller 30 determines a timing for keeping the valve 28 in an open state based on the most recent estimate or measurement of the flow parameters ( ⁇ P i,j ) and (R i,j ).
- the flow parameters are assumed (approximated) to be constant for at least the period of time that the valve 28 remains in a given position.
- the following equations are useful in determining the amount of agent delivered (s i ) in a prescribed dose period (T i ), and the prescribed dosage pharmacologically perceived,
- ⁇ P i,j open will often be assumed to be equal to ⁇ P i,j close for any given i,j.
- the position of the valve 28 simply changes the resistance magnitude (R) from R i,j open to R i,j close .
- R i,j open will often be approximated as equal to R i,j close and the position of the valve 28 simply changes the magnitude of ⁇ P from ⁇ P i,j open to ⁇ P i,j close .
- the unit dose period (t i,j ) is pre-determined, and t i,j open is calculated to effect the desired agent delivery.
- t i,j open is calculated to effect the desired agent delivery.
- the duration of the unit dose periods (t i,j ) is so chosen so that they are: (i) short enough that the flow parameters ( ⁇ P) and (R) are unlikely to change significantly so that the flow rates Q i,j open and Q i,j close can be approximated as being constant over the unit dose period (t i,j ); (ii) short enough that the open/close flow rate changes are pharmacologically imperceptible or insignificant; and (iii) long enough to achieve acceptable levels of battery consumption (by minimizing the number of battery-consuming opening and closing cycles for the valve 28 ).
- non-volatile memory 32 The above algorithms are maintained in non-volatile memory 32 , and RAM 34 is used as a work space for at least the purposes of the above calculations.
- the controller 30 is further coupled to an internalized power source 36 .
- FIG. 3 illustrates but one example of the control signals delivered from the controller 30 to the valve 28 .
- the illustrated signals extend over a period of time in which the potential output flow rate decreases.
- the duration of t l,x open is increased relative to the duration of, for example, t 1,t open for the “initial” dose periods (t i,j ).
- the noted change in t i,j open compensates for the change in infusate flow rate without express regard for the reason for such change in flow rate.
- the pressure generated by the drive source 16 will vary according to the volume of infusate remaining in the infusate reservoir 12 .
- the reservoir pressure drops as the reservoir volume is nearly depleted and rises as the reservoir volume nears (or exceeds) its rated capacity. In conventional infusion devices this is a liability because it affects and therefore reduces the flow rate accuracy and the usable volume of the infusate reservoir 12 .
- this information can be an asset that is used: (1) in the case of filled reservoirs, to alert a user so as to prevent a dangerous or undesirable overfilling of the pump; and/or (ii) in the case of nearly depleted reservoirs, to measure the volume of fluid remaining in the infusate reservoir 12 by measuring the reservoir pressure, and if appropriate, alert a user that the device should be refilled.
- the controller can use this information to adjust the open/close cycles, and thereby extend the usable volume of the infusion device without changing the physical size of the device.
- the duration of the flow period ( ⁇ ) can be limited by the compatibility or stability of an active agent in the infusate.
- “Compatibility” and “stability” are terms that are intended to capture all of the changes that can occur in the chemical, physical, pharmacological, or therapeutic properties of an infusate as it resides inside the infusate reservoir 12 of the drug delivery device. While not exhaustive, these changes include: (i) a decrease in the potency of the active ingredient; (ii) an increase in the potency of the active ingredient; and (iii) a change in infusate viscosity.
- the potency of morphine sulfate in conventional implantable infusion pumps is known to decrease by about 20% over a 90 day period, thus the lack of morphine stability restricts the maximum flow period for this agent to less than about 90 days (without regard to a potential volumetric capacity of the delivering infusion device).
- This fact, as well as the fact that some conventional constant flow implantable infusion pumps flow faster when full then they do when nearly empty, means that the actual drug dose received by the patient can vary dramatically over a flow period ( ⁇ ).
- look up tables or algorithms can be used to compensate for known changes in the properties of the infusate to adjust the flow controller over the course of the flow period ( ⁇ ). This has at least two beneficial effects: (i) a more uniform amount of active agent is administered throughout the flow period ( ⁇ ), thereby improving therapy and/or reducing side effects; and (ii) the maximum duration of the flow period ( ⁇ ) can be extended so that more of the infusate reservoir can be used.
- any internally powered, implantable device the life span of its power source dictates its functional life.
- removal and replacement of such device can be traumatic, required to undergo a surgical procedure to effect such removal and replacement.
- the benefits of any such implantable device are carefully weighed against the costs of use/replacement (e.g., hardware expense, physician time, hospitalization, etc.) as well as patient morbidity/mortality, it is imperative that efforts be made to provide an implantable device capable of sustaining sufficient operational life but remain cost and size effective.
- a rechargeable power source e.g., battery, capacity, etc.
- System power consumption is largely dictated by the power consumed to actuate the valve 28 through each open-close cycle for each unit dose (d i,j ) and generally, to a lesser extent, by that required to make the measurements and calculations required to control the valve timing. It is an objective of the present invention to safely minimize and control a total current drain associated with the operation of the valve 28 . This control increases the predictability of a life-span of a power source ( 36 , FIGS. 2A , 2 B, and 2 C). A generalized equation for current drain resulting from valve actuation for one unit dose cycle (t i,j ) is.
- I total I open +I held open ⁇ t i,j open +I close +I held close ⁇ t i,j close
- Shortening the duration of the unit dose period (t i,j ) improves flow accuracy, but at the expense of additional battery consumption to effect incremental valve actuation, computations, and pressure and/or temperature measurements. It will also be readily apparent that for reasons of battery conservation, there may be times and conditions within a given flow period ( ⁇ ) when the prescribed dose period (T i ) and/or unit dose period (t i,j ) should be lengthened or shortened, and that based on the design of the device it may be possible to predetermine these times (such as when the infusate reservoir is nearly empty), or to determine them in real time based on the input from a sensor.
- ⁇ P may change quickly meaning that the unit dose period (t i,j ) should be shortened to improve flow accuracy. Doing so, also effectively increases the amount of fluid from the infusate reservoir 12 that can be delivered within flow accuracy specifications (i.e., the usable volume), which is a very desirable feature.
- FIG. 4 illustrates a second embodiment of the present invention.
- Controller 50 communicates with the controller 30 through a patient's skin. Such communication is made, for example, using common radio-frequency technology that is well known in the art. The manner and form of communication is not critical. Any means (e.g., IR, direct connection, etc.) that is capable of establishing a data transfer link, provided that the controller 50 and the implantable infusion device are provided with the proper link components, is consistent with this aspect of the disclosed invention.
- Any means e.g., IR, direct connection, etc.
- the controller 50 can provide information (e.g., software updates, modification of calculation variables, for example, the unit dose period (t i,j ), t i,j open etc.) to the controller 30 for maintaining accurate functionality of the infusion device. Moreover, the controller 50 can provide instructions to the controller 30 to change any of these variables in response to changes in other parameters, e.g., complex continuous infusion.
- the controller 50 could also transmit power to the power source 36 , if the power source 36 was of a rechargeable nature. Further yet, the controller 50 could transmit power directly to the controller 30 via a carrier signal, e.g., using a radio-frequency carrier signal.
- the controller 50 preferably includes a display 50 a, which can communicate information, e.g., life expectancy of the power source 28 , to a user for real-time consideration. Additionally, diagnostic information regarding the operability of the implantable infusion device can be supplied to the user with only slight modification to the system illustrated in FIG. 2A .
- an infusion device in accordance with the present invention could be provided with a third pressure sensing device 40 , which is positioned downstream of the valve 28 . Further yet, additional variations of the specific arrangement of the components of this system are illustrated in FIGS. 5-11 .
- the following information can be gathered and supplied back to a monitoring user via a data link between the controller 30 and the controller 50 :
- transient responses from the second pressure sensing device 26 and the third pressure sensing device 40 during or proximate to an opening or closing of the valve 28 can be monitored to provide information regarding a system status. For example, in reference to the exemplary embodiment illustrated in FIG. 4 , if prior to opening the valve 28 , P R ⁇ P D1 ⁇ P D2 , then as the valve 28 is opened, a measured pressure transient enables a calculated appreciation of how freely infusate is able to flow through the catheter 22 and the flow restrictor 20 .
- the rate of change of pressures P D1 , and P D2 will communicate whether or not certain parts of the flow path are obstructed (e.g., completely or in part), and if obstructed, the location of such obstruction relative to the flow path. Moreover, as the valve 28 is closed, a measured pressure transient (between P D1 and P D2 ) will allow an inference as to how freely infusate is able flow form the infusate reservoir 12 through at least the restrictor 20 . A rate of change of pressure will communicate whether the system filter positioned between the infusate reservoir 12 and the restrictor 20 ) or the restrictor 20 is partially or completely obstructed as might occur over the lifetime of the device. Of course, this information could be displayed on the display 50 a. In a like manner, as the valve 28 is closed, a pressure transient measured for Pot will allow an inference as to how freely infusate is able to flow through the delivery catheter 22 .
- the data gained from the aforementioned detected conditions can enable a modification of controller variables (e.g., the unit dose period (t i,j ), t i,j open , etc.) so as to enable a targeted dosage/delivery rate to be maintained.
- controller variables e.g., the unit dose period (t i,j ), t i,j open , etc.
- the information gained can also provide the managing clinician with valuable information to help determine whether or not surgical intervention or a change in dosage is required.
- controller 50 has been described as a device capable of establishing a data transfer link, it should be further noted that modification of at least calculation variables (e.g., the unit dose period (t i,j ), t i,j open , etc.) can be accomplished through other non-invasive methods (e.g., trocar).
- modification of at least calculation variables e.g., the unit dose period (t i,j ), t i,j open , etc.
- non-invasive methods e.g., trocar
Abstract
The present invention relates to an implantable infusion pump having a refillable infusate reservoir in fluid communication with a delivery site via a flow path. This flow path includes a flow resistance. The infusion pump includes a sensing device(s), positioned relative to the flow path, to provide data regarding a flow rate along the flow path. The infusion pump effects a division of a total flow period into at least a plurality of unit dose periods, each unit dose period effecting delivery of a unit dose of infusate. The cumulative effect of delivering the total number of unit dose periods is the delivery of a desired dose over the total flow period. The present invention permits a reservoir pressure to vary over any portion of total flow period but effects a constant-pressure state over each unit dose cycle.
Description
- The present invention is a continuation of, and hereby claims priority to, copending and commonly assigned U.S. patent application Ser. No. 09/796,969 entitled “Non-Constant Pressure Infusion Pump,” filed Mar. 1, 2001, the disclosure of which is hereby incorporated herein by reference.
- The present invention relates to an implantable infusion pump, and in particular, to an infusion pump capable of effecting a precisely controlled (constant or variable) fluid flow delivery rate, independent of a constant reservoir pressure.
- Modern implantable infusion devices, or implantable pumps, for delivering an infusate (e.g., medicaments, insulin, etc.) commonly have a rigid housing that maintains a collapsible infusate reservoir. The housing includes a needle-penetrable septum that covers a reservoir inlet. A flow passage is provided between the reservoir and an exterior surface of the device. At the flow passage outlet, a flexible delivery catheter is provided.
- These devices are implanted at a selected location in a patient's body so that (i) the inlet septum is proximate to the patient's skin and (ii) a distal end of the catheter is positioned at a selected delivery site. Infusate can then be delivered to the infusion site by controlling the flow of such fluid from the device infusate reservoir into the delivery catheter. When the infusate reservoir becomes empty, the reservoir is refillable through the reservoir inlet by injecting a new supply of infusate through the apparatus' inlet septum. Due to the location of the device in relation to the skin of the patient, injection can be readily accomplished using a hypodermic needle (or cannula).
- Infusate is expelled from the reservoir to an infusion site by collapsing the reservoir. Some infusion pumps use an electrically powered mechanism to “actively” pump infusate from the infusate reservoir into the delivery catheter. Examples of these types of “active pumping” devices include so-called peristaltic pumps (e.g., SynchroMed® implantable pump from Medtronic, Inc., Minneapolis, Minn.) and accumulator-type pumps (e.g., certain external infusion pumps from Minimed, hIc., Northridge, Calif. and Infusaid® implantable pump from Strato/Infusaid, Inc., Norwood, Mass.). These devices have certain advantages; however, such devices have a large disadvantage in that they use relatively large amounts of battery power to effect infusion. Given that batteries tend to add bulk and weight and their replacement requires surgical intervention, it is very desirable to minimize power consumption in implantable infusion pumps.
- Another type of implantable pump that is typically much more electrically efficient uses a passive pumping mechanism. In fact, certain of these devices can be constructed and operated without any electrical power at all. A passive pumping mechanism generally consists of a means of pressurizing the infusate reservoir and a means of restricting the fluid flow. All of these devices operate under the principle that the fluid flow rate (Q) is directly proportional to a pressure difference (ΔP) between the infusate reservoir interior and the delivery site and inversely proportional to the total flow resistance provided by the fluid passage and delivery catheter (collectively (R)), wherein
-
Q=ΔP÷R - The first means of developing such a “constant pressure source” includes using a two-phase fluid, or propellant, that is contained within the rigid housing and is further confined within a fluid-tight space adjacent to the infusate reservoir. Pumps constructed in this manner are called “gas-driven” pumps.
- The propellant is both a liquid and a vapor at patient physiological temperatures, e.g., 98.6° F., and theoretically exerts a positive, constant pressure over a full volume change of the reservoir, thus effecting the delivery of a constant flow of infusate. When the infusate reservoir is expanded upon being refilled, a portion of such vapor reverts to its liquid phase and thereby maintains a state of equilibrium between the fluid and gas states at a “vapor pressure,” which is a characteristic of the propellant. The construction and operation of implantable infusion pumps of this type are described in detail, for example, in U.S. Pat. Nos. 3,731,681 and 3,951,147. Pumps of this type are commercially available, for example Model 3000™ form Arrow International, Reading, Pa. and IsoMed® from Medtronic, Inc., Minneapolis, Minn.
- Gas-driven infusion pumps typically provide an electrically efficient means to deliver a flow of infusate throughout a delivery cycle. However, such infusion pumps depend upon a constant pressure source, wherein the output fluid flow rate is directly proportional to a propellant-reservoir pressure. If the propellant-reservoir pressure varies, then so will the fluid flow rate and the drug delivery rate.
- The propellant-reservoir pressure of conventional gas-driven infusion pumps are susceptible to changes in ambient temperature and pressure. This, in turn, makes the fluid flow rate such devices susceptible to changes in ambient temperature and pressure. Such changes in drug infusion rates are undesirable and, in certain situations, unacceptable.
- Circumstances readily exist where either ambient temperature or pressure can rapidly change a significant amount. For example, the reservoir pressure of some conventional gas-driven pumps can change as much as 0.5 psi for each 1° F. change in body temperature. Thus, for example, assuming a pump driving force of 8 psi at 98.6° F., a fever of only 102.6° F. can result in a twenty-five percent (25%) increase in propellant-reservoir pressure and thus, a corresponding (or larger) increase in an fluid flow rate. In addition, changes in environmental temperature affect the infusate viscosity as well as the vapor pressure produced by the propellant, thereby further increasing the pump's susceptibility to temperature.
- An even more serious situation results from changes in ambient pressure. Although minor variations in ambient pressure at any given location on earth may not significantly affect delivery flow rates, with modern modes of transportation, a patient can rapidly change altitude during travel, such as when traveling in the mountains or when traveling by plane. In a like manner, a patient can experience a rapid change in pressure when swimming or diving.
- The rigid housing of the conventional, gas-driven infusion pump provides an absolute constant-internal pressure (PR) (at constant temperature) independent of external pressures. However, largely due to compliance by the lungs and venous circulatory system, hydrostatic pressure within the human body closely follows ambient pressure (PD).
- The net effect is that the pressure differential (ΔP=PR−PD) in conventional gas-driven pumps changes linearly with ambient pressure. Consequently, a delivered infusate flow rate can increase as much as forty percent (40%) when a patient takes a common commercial airline flight.
- To overcome these practical circumstances, some conventional gas-driven infusion devices have been provided with elevated reservoir pressures. The increased reservoir pressures are not intended to prevent variations in a constant pressure delivery but are intended to mitigate their effect. In particular, for any given change of pressure, the effect on flow rate is effectively lessened if the total percentage of pressure change (relative to the reservoir pressure) can be reduced. These infusion devices possess undesirable attributes in that refilling operations are more difficult and the high-pressure vessels, which form the pump housing structures, must necessarily be stronger and are therefore more susceptible to manufacturing problems.
- Another method of attempting to produce a constant pressure source and thereby more accurately controlling a rate of fluid delivery is to incorporate a pressure regulator, such as that disclosed in U.S. Pat. No. 4,299,220. The pressure regulator described therein, which is positioned between the infusate reservoir and delivery catheter, uses a diaphragm valve to maintain a constant pressure differential (OP) across the fluid flow restrictor. In addition to increasing the operational complexity of such a pump mechanism and the volume of a fluid path extending therethrough, the pressure regulator may, depending upon device configuration, subject infusate solutions to high local shear stresses, which may alter the chemical or therapeutic properties of certain infusates.
- An alternative method for attempting to produce a constant pressure source and thereby more accurately controlling a rate of fluid delivery, as well as addressing the susceptibilities of the two-phase pumps to ambient temperature and pressure, is proposed in U.S. Pat. No. 4,772,263. Specifically, in place of the conventional rigid enclosure that maintains a two-phase fluid, the disclosure teaches forming the fluid reservoir between a rigid portion (which maintains at least the inlet septum) and a flexible drive-spring diaphragm. The spring diaphragm is exposed to the body of the patient and the pressure therein. The spring diaphragm creates a more desirable “relative” (as opposed to an absolute) pressure source. By exposing the spring diaphragm to the pressures inside the body it is possible for the pump to respond and react to changes in ambient pressure so that AP is unaffected. Likewise, it is possible to construct the spring diaphragm so that the pressure that it generates is not affected by changes in ambient temperature. While this configuration offers practical performance advantages, this design offers a unique configuration that may not be adopted by all constant flow pump designs.
- Accordingly, a need exists for an electrically efficient system to enable a controllable (constant or variable) fluid flow delivery rate independent of either a constant reservoir pressure or external conditions that may otherwise result in undesirable or unpredictable output fluid flow variations.
- An object of the present invention is to provide an implantable infusion device with a non-constant reservoir pressure (over at least a portion of the flow cycle) that controls fluid flow across a fluid flow restrictor (with or without other fluid control elements) by dividing a greater dose cycle into a series of (smaller) unit dose cycles over which the reservoir pressure is substantially constant.
- Another object of the present invention is to provide an electrically efficient implantable infusion device, having a convenient pressure reservoir, that is capable of delivering a prescribed dosage of a fluid infusate independent of either a constant reservoir pressure, ambient temperature or pressure, changes in device performance, or infusate properties.
- Another objective of the present invention is to provide an implantable infusion device that is simpler in construction.
- The present invention is directed to a controlled-rate infusion device for implantation in a living body. The infusion device includes a collapsible infusate chamber, an energy source to collapse the chamber, and an outlet flow path extending between the chamber and a device outlet. The infusion device further includes at least one flow restrictor, a controller, at least one valve or variable flow restrictor to selectively alter a flow resistance of the outlet flow path, and at least one pressure sensing device. The pressure sensing device(s) are positioned relative to the outlet flow path as well as about the flow resistance (i.e., any combination of flow restrictors and/or valves). The controller is adapted to control an operation of the valve (or variable flow restrictor) based on measured value(s) obtained by the pressure sensing device(s).
- In another aspect, the present invention is directed to a controlled-rate infusion device for implantation in a living body. The infusion device includes a collapsible infusate chamber, an energy source to collapse the chamber, and an outlet flow path extending between the chamber and a device outlet. The infusion device further includes a controller, a valve (or variable flow restrictor) to selectively obstruct the outlet flow path, and one or more pressure sensing devices. The pressure sensing devices are positioned relative to the outlet flow path as well as about the flow resistance. The controller is adapted to assess whether output flow from the device is undesirably restricted based on measured values obtained from the pressure sensing devices.
- Another aspect of the present invention is directed to a method for controlling infusate output from an implantable-infusion device for a prescribed dose period. The device includes a collapsible infusate chamber, an energy source to collapse the chamber, and an outlet flow path extending between the chamber and a device outlet, and the outlet flow path includes a restrictor network, which includes an occlude the outlet flow path. The method includes the steps of: (i) dividing the prescribed dose period into a plurality of unit dose periods, wherein each unit dose period is defined by an open-close cycle of the valve; and (ii) modifying a duty cycle of the open-close cycle of the valve so as to maintain a prescribed output volume (i.e., a unit dose) for each unit dose period.
- Another aspect of the method for controlling infusate output from an implantable infusion device can include, independent of or in cooperation with other aspects of this method, measuring an infusate pressure differential across the restrictor network (or a portion thereof). Thus, the step of modifying the duty cycle is performed in accordance with a measured infusate pressure differential.
- Another aspect of the method for controlling infusate output from an implantable infusion device can include, independent of or in cooperation with other aspects of this method, actuating the valve so as to effect a change in an occluded state of the outlet flow path. During or proximate to such actuation, a transient pressure profile on one side of the valve is measured, thus enabling an assessment of the performance of the valve, fluid path, flow restrictor and any other elements of the flow control system or flow path.
- Another aspect of the method for controlling infusate output from an implantable infusion device can include, independent of or in cooperation with other aspects of this method, measuring an infusate temperature. Thus, the step of modifying the duty cycle is performed in accordance with a measured infusate temperature.
- Another aspect of the present invention is that an output flow rate of a controlled rate pump can be changed by “resetting,” or programming, such output flow rate. This resetting operation can be accomplished using non-invasive (e.g., magnetic switch, radio-frequency telemetry) or invasive methods (e.g., transcutaneous trocar). In this way, the methods and devices described herein can be used to construct a programmable pump, the flow rate of which can be manually or automatically (responsive to a clock, sensor, or other data input) modified to any of various beneficial patterns.
- Other objects and advantages of the present invention will be apparent to those of ordinary skill in the art having reference to the following specification together with the drawings.
- In the drawings, like reference numerals and letters indicate corresponding parts throughout the several illustrations:
-
FIG. 1 schematically illustrates a conventional implantable infusion device for delivering an infusate at a prescribed rate incorporating a passive pumping mechanism; -
FIG. 2A schematically illustrates an implantable infusion device in accordance with one embodiment of the present invention,FIG. 2B schematically illustrates an implantable infusion device in accordance with another embodiment of the present invention, andFIG. 2C schematically illustrates an implantable infusion device in accordance with another embodiment of the present invention; -
FIG. 3 illustrates an exemplary timing chart corresponding to valve control for regulating a delivery of infusate from an infusate reservoir of the implantable infusion device of eitherFIG. 2A , 2B, orFIG. 2C ; -
FIG. 4 schematically illustrates an implantable infusion device in accordance with another embodiment of the present invention; -
FIG. 5 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention; -
FIG. 6 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention; -
FIG. 7 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention; -
FIG. 8 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention. -
FIG. 9 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention; -
FIG. 10 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention; and -
FIG. 11 partially illustrates a schematic representation of an implantable infusion device in accordance with another embodiment of the present invention. - Various embodiments, including preferred embodiments, will now be described in detail below with reference to the drawings.
-
FIG. 1 illustrates a conventional, constant flowrate infusion device 10. Thedevice 10 is characterized by aninfusate reservoir 12 that is required to store a prescribed volume of infusate, e.g., insulin, medicament, pain relieving drugs, etc. Theinfusate reservoir 12 is of sufficient volume so as to provide a supply of infusate (i.e., a prescribed dose (D)) over a flow period (τ) at a (theoretically) constant flow rate. As but one possible example, the volume of theinfusate reservoir 12 can be fixed at any prescribed volume to enable delivery of a precisely controlled volume of infusate from one day to more than three months. Theinfusate reservoir 12 can be refilled through aseptum 14. - Infusate is pressurized and thereby driven from the
infusate reservoir 12 by adrive source 16. The physical nature of thedrive source 16 can be a two-phase fluid, which is confined between the housing of thedevice 10 and amovable diaphragm structure 18, a drive spring that forms thediaphragm structure 18, or like mechanisms/structures that develop a substantially constant pressure. Aflow restrictor 20 is positioned downstream from theinfusate reservoir 12 to establish an output flow rate. The flow restrictor 20 can be constructed of any number of potential structures, for example, a plate having a groove formed therein, capillary tubing, an etched flow chip, or the like. Although not shown, a filter is preferably interpositioned between theinfusate reservoir 12 and the restrictor 20 to prevent any bacteria present in theinfusate reservoir 12 from being transferred into the body, and to a certain extent, to protect the restricted flow path defined by therestrictor 20. Flow from theflow restrictor 20 is passed to acatheter 22 having its distal end positioned at a site for fluid delivery. - Conventional implantable infusion devices can further include a
bolus port structure 24. Thebolus port structure 24, whether integral with thedevice 10 or separate therefrom, provides direct fluid communication with thecatheter 22. Thebolus port structure 24 is adapted to receive independently a hypodermic needle (or cannula). Fluid delivered to thebolus port structure 24 can be used to flush thedownstream catheter 22, deliver a prescribed dosage of medicament (possibly of a volume greater or at a rate greater than that otherwise capable to be delivered through the flow restriction 20), or perform troubleshooting or diagnostic procedures. Depending on the configuration of thebolus port structure 24, thestructure 24 can also allow extraction of fluid from the patient via thecatheter 22. -
FIG. 2A illustrates one embodiment of the present invention. Specifically, an implantable infusion device has ainfusate reservoir 12 connected between aseptum 14 and aflow restrictor 20. Infusate within theinfusate reservoir 12 is pressurized and thereby driven through theflow restrictor 20 by thedrive source 16. The illustrated infusion device includes a firstpressure sensing device 24, to measure a pressure upstream of theflow restrictor 20, and a secondpressure sensing device 26, to measure a pressure downstream of theflow restrictor 20. Respective positions of thepressure sensing devices pressure sensing device 24 remains upstream of theflow restrictor 20 and thepressure sensing device 26 remains downstream of theflow restrictor 20. Alternatively, given that the flow rate will be determined by a pressure differential (ΔP) at the point of thepressure sensing devices pressure sensing devices 24 and 26 (FIG. 2A orFIG. 4 ) or as otherwise occupied by thepressure sensing devices 24 and 40 (FIG. 4 ), as illustrated inFIGS. 2B and 2C . - It will be readily apparent to those of ordinary skill in the art that a multitude of configurations are within the scope of the present invention, such configurations including at least one flow restrictor, one pressure sensor, and a mechanism to change the total flow resistance of the system. To this end,
FIGS. 2A to 11 illustrate some of the possible configuration-combinations that includes: (i) one or more flow restrictors arranged in parallel, series, or combinations thereof, (ii) one or more valves, whereby these elements can affect an overall flow resistance; and (iii) one or more pressure sensors that are capable of determining a pressure difference across any portion of or all of the flow restrictors or valves. In regard to (ii) above, depending upon the intended use of the infusion device, it may be desirable to use fixed or variable flow restrictors, which includes mono-stable, bi-stable, or multi-stable valves that have the potential of occluding or partially occluding the possible flow paths. - A
valve 28 is positioned downstream of theflow restrictor 20, and is preferably positioned downstream of thepressure sensing device 26. Accordingly, thepressure sensing device 24 can be 24 can be positioned within or proximate to theinfusate reservoir 12, and thepressure sensing device 26 can be positioned subsequent to thevalve 28. - A controller 30 (e.g., a microprocessor) is electrically connected to the
pressure sensing device 24, thepressure sensing device 26, and thevalve 28. The controlled 30 functions to control fluid flow through thevalve 28 based on respective outputs formpressure sensing devices - A fluid flow rate across the
flow restrictor 20 can be calculated from: -
Q=(P R −P D)÷R - where,
-
- Q is a flow rate output from the
catheter 22; - PR is a measured reservoir pressure;
- PD is a measured delivery pressure; and
- R is a flow resistance value of the flow path as a whole, which can be approximated by the resistive value of the flow restrictor 20 (when the valve is in an open state).
- Q is a flow rate output from the
- An optional
temperature sensing device 38 can also be coupled to thecontroller 30. If provided, thecontroller 30 would function to control fluid flow through thevalve 28 also in consideration of (or solely based on) an output from thetemperature sensing device 38. Thecontroller 30 is adapted to relate changes in an infusate temperature to proportional changes in system pressure and/or to changes in the resistive value (R), the latter being caused by a change in fluid viscosity due to a change in infusate temperature. This ability of thecontroller 30 is managed by algorithm or look-up tables stored inmemories 32 and/or 34. - A flow cycle of an infusion device is considered to extend through the delivery of the contents of the
infusate reservoir 12, i.e., from a refilling event until a subsequent refilling event. The quantity (S) of active pharmacological agents or other agents (individually or collectively “agent”) contained in theinfusate reservoir 12 depends upon the fluid volume (V) of theinfusate reservoir 12 and the concentration of the agent in the infusate stored therein: -
S=V*C - where,
-
- S is the quantity (e.g., mg) of the agent,
- C is the agent concentration in the infusate contained in the
infusate reservoir 12, and - V is the fluid volume of the
infusate reservoir 12.
- The duration of the flow cycle is referred to as the flow period (τ). As is probable, the flow period will typically be between 1 and over three (3) months. It is related to the flow rate (Q) and the infusate reservoir volume (V) as follows:
-
τ=V÷Q - where,
-
- τ is the flow period (e.g., days), and
- Q is the infusate flow rate (e.g., ml/day).
- A prescribed (or desired) dose (D) delivered must be further calculated in accordance with the following:
-
D=Q*C - where,
-
- D is the quantity of an agent delivered per unit of time (e.g., mg/day).
As discussed above, conventional constant flow infusion devices deliver a single prescribed dose (D) based on the assumption that a constant pressure is maintained over an entire flow period (τ). As also discussed above, this assumption can be realistically compromised by changes in ambient pressure or temperature, patient position, or infusate volume residing in the reservoir throughout a flow period (τ). Moreover, the total flow resistance (R) provided by the flow path can change over the lifetime of the infusion device further affecting the discharge performance of the device. Moreover, the properties of the infusate can change over the lifetime of the infusion device, further affecting the therapy.
- D is the quantity of an agent delivered per unit of time (e.g., mg/day).
- In contrast, the devices of the present invention seek to provide the desired flow accuracy in spite of the fact that the pressure differential (ΔP) and/or flow resistance (R) may not remain constant over the entire flow period (τ). These devices do this by subdividing the flow period (τ) into smaller unit dose periods (ti,j) over which the flow parameters (ΔP) and (R) are likely to remain constant and delivering the total dose (D) though a series of sequential unit dose periods (ti,j). The following definitions and equations help to understand the present invention.
- A flow period (τ) can be subdivided into any number (n) of prescribed dose periods (Ti), which may or may not be of equal duration. For conventional constant flow pumps, n=1. For the present invention, “n” may be any integer, preferably two or greater.
-
- For various embodiments of the present invention, the duration of the prescribed dose periods (Ti) may or may not be physician-alterable (i.e., to create a programmable pump) and/or patient-alterable (i.e., to create a programmable pump with patient-controllable elements) either before or during the flow period (τ).
- During each of the prescribed dose periods (Ti) a prescribed dose (Di) is delivered. If all of these prescribed doses (Di) are equal, then the equations describe a constant flow infusion device, possibly with improved flow accuracy such as, for example, illustrated in
FIG. 2A . If these are multiple prescribed doses (Di) of different magnitudes, then the equations describe a programmable pump operating with a complex continuous infusion pattern. The therapeutic value of theses complex infusion patterns is readily apparent to clinicians, and varies depending upon the agent, patient, and application. - In all applications, a certain quantity of drug (si) is to be delivered in the dose period (Ti) at a prescribed dose (Di). The following equations illustrate the relationship among these variables,
-
- In the present invention, each of the prescribed dose periods (Ti) is further divided into any number (mi) of unit dose periods (ti,j). For the present invention, “m” may be any integer, one or greater. In a preferred embodiment, all of the unit dose periods (ti,j) within a given prescribed dose period (Ti) are equal. This simplifies the calculations necessary for device operation; however, this is not a necessary condition. In general,
-
- when all unit dose periods (ti,j) within each of the prescribed dose periods (Ti) are equal,
-
- During each unit dose period (ti,j), the
valve 28 will be actuated through one complete cycle, such that it is in one position (i.e., designated open) for a fraction of the unit dose period (ti,j) and in a second position (i.e., designated closed) for the balance of the unit dose period (ti,j). Those skilled in the art will readily appreciate that it would also be possible to use one or more valves to move between two or more position during any given unit dose period (ti,j), and it would also be possible for such valve(s) to move between different positions during the same or different unit dose periods (ti,j). - In the simplified embodiment described herein, the
controller 30 determines a timing for keeping thevalve 28 in an open state based on the most recent estimate or measurement of the flow parameters (ΔPi,j) and (Ri,j). The flow parameters are assumed (approximated) to be constant for at least the period of time that thevalve 28 remains in a given position. The following equations are useful in determining the amount of agent delivered (si) in a prescribed dose period (Ti), and the prescribed dosage pharmacologically perceived, -
- where
-
- ti,j open is the duration of time that the
valve 28 is in an open state, - ti,j close is the duration of time that the
valve 28 is in a closed state, - Qi,j open is the flow rate when the
valve 28 is in the open state during unit dose period ti,j, and - Qi,j close is the flow rate when the
valve 28 is in the closed state during unit dose period ti,j.
- ti,j open is the duration of time that the
- For passive pumping devices, the flow rate can be further described by the following equations,
-
Q i,j open =ΔP i,j open ÷R i,j open -
Q i,j close =ΔP i,j close ÷R i,j close - For restrictor-based passive pumping devices, ΔPi,j open will often be assumed to be equal to ΔPi,j close for any given i,j. Thus, the position of the
valve 28 simply changes the resistance magnitude (R) from Ri,j open to Ri,j close. For passive pumping devices incorporating a regulator, Ri,j open will often be approximated as equal to Ri,j close and the position of thevalve 28 simply changes the magnitude of ΔP from ΔPi,j open to ΔPi,j close. - While in many cases Qi,j close will be a zero value, i.e., the
valve 28 closes completely and flow stops, such is not a necessary condition. For example, if maintaining the valve is an open state uses battery power, then it may be advantageous to design the infusion device to have a non-zero Qi,j close flow rate to thereby reduce the amount of time that thevalve 28 needs be held open, and thereby conserve battery power. Alternatively, it may be possible to use a longer unit dose period (ti,j) when using a non-zero Qi,j close flow rate, and thereby reduce battery consumption by reducing the total number of unit dose periods. In cases when Qi,j close is zero the equation simplifies to, -
- In a preferred embodiment, the unit dose period (ti,j) is pre-determined, and ti,j open is calculated to effect the desired agent delivery. Those skilled in the art will readily recognize that it is possible to obtain the same effect by pre-determining ti,j open and calculating ti,j close, and thereby calculating ti,j so that effectively ti,j open is held constant while ti,j is varied.
- The duration of the unit dose periods (ti,j) is so chosen so that they are: (i) short enough that the flow parameters (ΔP) and (R) are unlikely to change significantly so that the flow rates Qi,j open and Qi,j close can be approximated as being constant over the unit dose period (ti,j); (ii) short enough that the open/close flow rate changes are pharmacologically imperceptible or insignificant; and (iii) long enough to achieve acceptable levels of battery consumption (by minimizing the number of battery-consuming opening and closing cycles for the valve 28).
- The above algorithms are maintained in
non-volatile memory 32, andRAM 34 is used as a work space for at least the purposes of the above calculations. Thecontroller 30 is further coupled to an internalizedpower source 36. - Reference is hereby made to
FIG. 3 , which illustrates but one example of the control signals delivered from thecontroller 30 to thevalve 28. The illustrated signals extend over a period of time in which the potential output flow rate decreases. For the exemplary illustrated unit dose periods (ti,j), the duration of tl,x open is increased relative to the duration of, for example, t1,t open for the “initial” dose periods (ti,j). Notwithstanding, the duration of the unit dose period (t1,m,=tl for all of m) is held constant. Of course, the noted change in ti,j open compensates for the change in infusate flow rate without express regard for the reason for such change in flow rate. - In some devices the pressure generated by the
drive source 16 will vary according to the volume of infusate remaining in theinfusate reservoir 12. For example, in many devices the reservoir pressure drops as the reservoir volume is nearly depleted and rises as the reservoir volume nears (or exceeds) its rated capacity. In conventional infusion devices this is a liability because it affects and therefore reduces the flow rate accuracy and the usable volume of theinfusate reservoir 12. However, in the present invention this information can be an asset that is used: (1) in the case of filled reservoirs, to alert a user so as to prevent a dangerous or undesirable overfilling of the pump; and/or (ii) in the case of nearly depleted reservoirs, to measure the volume of fluid remaining in theinfusate reservoir 12 by measuring the reservoir pressure, and if appropriate, alert a user that the device should be refilled. As described earlier, the controller can use this information to adjust the open/close cycles, and thereby extend the usable volume of the infusion device without changing the physical size of the device. - In some clinical applications, the duration of the flow period (τ) can be limited by the compatibility or stability of an active agent in the infusate. “Compatibility” and “stability” are terms that are intended to capture all of the changes that can occur in the chemical, physical, pharmacological, or therapeutic properties of an infusate as it resides inside the
infusate reservoir 12 of the drug delivery device. While not exhaustive, these changes include: (i) a decrease in the potency of the active ingredient; (ii) an increase in the potency of the active ingredient; and (iii) a change in infusate viscosity. For example, the potency of morphine sulfate in conventional implantable infusion pumps is known to decrease by about 20% over a 90 day period, thus the lack of morphine stability restricts the maximum flow period for this agent to less than about 90 days (without regard to a potential volumetric capacity of the delivering infusion device). This fact, as well as the fact that some conventional constant flow implantable infusion pumps flow faster when full then they do when nearly empty, means that the actual drug dose received by the patient can vary dramatically over a flow period (τ). - However, in the present invention look up tables or algorithms can be used to compensate for known changes in the properties of the infusate to adjust the flow controller over the course of the flow period (τ). This has at least two beneficial effects: (i) a more uniform amount of active agent is administered throughout the flow period (τ), thereby improving therapy and/or reducing side effects; and (ii) the maximum duration of the flow period (τ) can be extended so that more of the infusate reservoir can be used.
- For any internally powered, implantable device, the life span of its power source dictates its functional life. Of course, removal and replacement of such device can be traumatic, required to undergo a surgical procedure to effect such removal and replacement. As the benefits of any such implantable device are carefully weighed against the costs of use/replacement (e.g., hardware expense, physician time, hospitalization, etc.) as well as patient morbidity/mortality, it is imperative that efforts be made to provide an implantable device capable of sustaining sufficient operational life but remain cost and size effective. Even when the device incorporates a rechargeable power source (e.g., battery, capacity, etc.) minimizing power consumption is desirable.
- System power consumption is largely dictated by the power consumed to actuate the
valve 28 through each open-close cycle for each unit dose (di,j) and generally, to a lesser extent, by that required to make the measurements and calculations required to control the valve timing. It is an objective of the present invention to safely minimize and control a total current drain associated with the operation of thevalve 28. This control increases the predictability of a life-span of a power source (36,FIGS. 2A , 2B, and 2C). A generalized equation for current drain resulting from valve actuation for one unit dose cycle (ti,j) is. -
I total =I open +I held open ·t i,j open +I close +I held close ·t i,j close - where,
-
- for a bi-stable valve, Iheld open and Iheld close are zero values, thus Itotal=Iopen+Iclose; and by comparison,
- for a mono-stable valve, Iclose and Iheld close are likely zero values, thus Itotal=Iopen+Iheld open·ti,j open.
- Shortening the duration of the unit dose period (ti,j) improves flow accuracy, but at the expense of additional battery consumption to effect incremental valve actuation, computations, and pressure and/or temperature measurements. It will also be readily apparent that for reasons of battery conservation, there may be times and conditions within a given flow period (τ) when the prescribed dose period (Ti) and/or unit dose period (ti,j) should be lengthened or shortened, and that based on the design of the device it may be possible to predetermine these times (such as when the infusate reservoir is nearly empty), or to determine them in real time based on the input from a sensor. For example, when the reservoir is nearly depleted, ΔP may change quickly meaning that the unit dose period (ti,j) should be shortened to improve flow accuracy. Doing so, also effectively increases the amount of fluid from the
infusate reservoir 12 that can be delivered within flow accuracy specifications (i.e., the usable volume), which is a very desirable feature. - Based on a flow rate determined by the
controller 30, an accurate, dynamic calculation of remaining power source life can be made. Likewise, an estimated life for thepower source 36 can be approximated from anticipated changes of the infusion device, or the present invention can be configured to pass calculated, real-time information outside the patient to anexternal controller 50. For this concept, reference is made toFIG. 4 , which illustrates a second embodiment of the present invention. -
Controller 50 communicates with thecontroller 30 through a patient's skin. Such communication is made, for example, using common radio-frequency technology that is well known in the art. The manner and form of communication is not critical. Any means (e.g., IR, direct connection, etc.) that is capable of establishing a data transfer link, provided that thecontroller 50 and the implantable infusion device are provided with the proper link components, is consistent with this aspect of the disclosed invention. - The
controller 50 can provide information (e.g., software updates, modification of calculation variables, for example, the unit dose period (ti,j), ti,j open etc.) to thecontroller 30 for maintaining accurate functionality of the infusion device. Moreover, thecontroller 50 can provide instructions to thecontroller 30 to change any of these variables in response to changes in other parameters, e.g., complex continuous infusion. Thecontroller 50 could also transmit power to thepower source 36, if thepower source 36 was of a rechargeable nature. Further yet, thecontroller 50 could transmit power directly to thecontroller 30 via a carrier signal, e.g., using a radio-frequency carrier signal. - It is contemplated that through the communication link between the
controller 30 and thecontroller 50, data can be uploaded from thecontroller 30 to thecontroller 50. To this end, thecontroller 50 preferably includes adisplay 50 a, which can communicate information, e.g., life expectancy of thepower source 28, to a user for real-time consideration. Additionally, diagnostic information regarding the operability of the implantable infusion device can be supplied to the user with only slight modification to the system illustrated inFIG. 2A . - In further reference to
FIG. 4 , an infusion device in accordance with the present invention could be provided with a thirdpressure sensing device 40, which is positioned downstream of thevalve 28. Further yet, additional variations of the specific arrangement of the components of this system are illustrated inFIGS. 5-11 . - From the initial
pressure sensing devices 24 and 26 (and the optional third pressure sensing device 40), the following information can be gathered and supplied back to a monitoring user via a data link between thecontroller 30 and the controller 50: -
- Valve open, if PR>PD1≅PD2;
- Valve closed, if PR≅PD1>PD2;
- Catheter obstruction (e.g., kink, thrombosis), if
- PR≅PD1≅PD2
- Further yet, transient responses from the second
pressure sensing device 26 and the thirdpressure sensing device 40 during or proximate to an opening or closing of thevalve 28 can be monitored to provide information regarding a system status. For example, in reference to the exemplary embodiment illustrated inFIG. 4 , if prior to opening thevalve 28, PR≅PD1≧PD2, then as thevalve 28 is opened, a measured pressure transient enables a calculated appreciation of how freely infusate is able to flow through thecatheter 22 and theflow restrictor 20. The rate of change of pressures PD1, and PD2 will communicate whether or not certain parts of the flow path are obstructed (e.g., completely or in part), and if obstructed, the location of such obstruction relative to the flow path. Moreover, as thevalve 28 is closed, a measured pressure transient (between PD1 and PD2) will allow an inference as to how freely infusate is able flow form theinfusate reservoir 12 through at least the restrictor 20. A rate of change of pressure will communicate whether the system filter positioned between theinfusate reservoir 12 and the restrictor 20) or the restrictor 20 is partially or completely obstructed as might occur over the lifetime of the device. Of course, this information could be displayed on thedisplay 50 a. In a like manner, as thevalve 28 is closed, a pressure transient measured for Pot will allow an inference as to how freely infusate is able to flow through thedelivery catheter 22. - Provided that the critical portion of the flow path (i.e., that portion through which regardless of any/all valve states all infusate must flow) within the
infusion device 10 is not completely occluded, the data gained from the aforementioned detected conditions can enable a modification of controller variables (e.g., the unit dose period (ti,j), ti,j open, etc.) so as to enable a targeted dosage/delivery rate to be maintained. The information gained can also provide the managing clinician with valuable information to help determine whether or not surgical intervention or a change in dosage is required. - As should also be noted, while the
controller 50 has been described as a device capable of establishing a data transfer link, it should be further noted that modification of at least calculation variables (e.g., the unit dose period (ti,j), ti,j open, etc.) can be accomplished through other non-invasive methods (e.g., trocar). - While the invention has been described herein relative to a number of particularized embodiments, it is understood that modifications of, and alternatives to, these embodiments, in particular, variants in the number, type, and configuration of the flow restrictor(s), valve(s), and sensor(s), such modifications and alternatives realizing the advantages and benefits of this invention, will be apparent those of ordinary skill in the art having reference to this specification and its drawings. It is contemplated that such modifications and alternatives are within the scope of this invention as subsequently claimed herein, and it is intended that the scope of this invention claimed herein be limited only by the broadest interpretation of the appended claims to which the inventors are legally entitled.
Claims (21)
1. A system for infusing a fluid in a living body, said system comprising:
a reservoir to transiently store a fluid infusate for transmission to a delivery site;
a flow restrictor disposed in a fluid path between said reservoir and said delivery site;
a pressure sensing device providing pressure information to determine a pressure differential across said flow restrictor; and
a valve disposed in said fluid path between said reservoir and said delivery site, said valve operable to control infusate output from said reservoir to said delivery site as a function of said pressure differential across said flow restrictor;
wherein said reservoir, said flow restrictor, said pressure sensing device, and said valve are provided in a configuration adapted for implantation in a living body.
2. The system of claim 1 , further comprising: an energy source to effect an expulsion of stored infusate from said reservoir.
3. The system of claim 2 , wherein said energy source provides a non-constant reservoir pressure, and wherein said valve is controlled to provide a desired flow of said infusate despite said non-constant reservoir pressure.
4. The system of claim 3 , further comprising:
a controller coupled to said pressure sensing device and said valve, said controller operable to utilize said pressure information to determine said pressure differential across said flow restrictor, said controller further operable to subdivide a flow period into smaller unit dose periods over which said pressure differential across said flow restrictor is likely to remain constant and controlling said valve to deliver a total dose of said infusate through a series of sequential said unit dose periods.
5. The system of claim 4 , wherein said unit dose periods are selected at least in part to reduce battery consumption.
6. The system of claim 4 , wherein said unit dose periods are selected so that an open/close rate of said valve is pharmacologically insignificant.
7. The system of claim 1 , further comprising:
a controller coupled to said pressure sensing device and said valve, said controller operable to utilize said pressure information to determine said pressure differential across said flow restrictor, said controller further operable to manipulate said valve as a function of said pressure differential across said flow restrictor and thereby control infusate output from said variable-volume chamber to said delivery site.
8. The system of claim 7 , wherein said controller provides an alert with respect to overfilling of said reservoir using said pressure differential across said flow restrictor.
9. The system of claim 7 , wherein said controller provides an alert with respect to depletion of said reservoir using said pressure differential across said flow restrictor.
10. The system of claim 7 , wherein said controller further determines a rate at which said pressure differential across said flow restrictor changes.
11. The system of claim 10 , wherein said controller alters timing of a period of said valve being opened as a function of said rate at which said pressure differential across said flow restrictor changes.
12. The system of claim 1 , wherein said pressure sensing device comprises:
a first pressure sensor disposed in said fluid path between said outlet conduit and said flow restrictor; and
a second pressure sensor disposed in said fluid path between said flow restrictor and said delivery site.
13. The system of claim 12 , wherein said pressure sensing device further comprises:
a third pressure sensor disposed in said fluid path between said second pressure sensor and said delivery site.
14. The system of claim 1 , further comprising:
a temperature sensing device providing temperature information to determine a temperature of said infusate.
15. The system of claim 14 , wherein said valve is further operable to control infusate output from said reservoir as a function of said temperature of said infusate.
16. A method for infusing a fluid in a living body, said method comprising:
providing a reservoir, a flow restrictor, and a valve in a configuration adapted for implantation in a living body;
transiently storing a fluid infusate in said reservoir for transmission to a delivery site;
disposing said flow restrictor in a fluid path between said reservoir and said delivery site;
determining a pressure differential across said flow restrictor; and
controlling said valve disposed in said fluid path between said reservoir and said delivery site to control infusate output from said reservoir to said delivery site as a function of said pressure differential across said flow restrictor.
17. The method of claim 16 , wherein controlling said valve comprises:
subdividing a flow period into smaller unit dose periods over which said pressure differential across said flow restrictor is likely to remain constant and controlling said valve to deliver a total dose of said infusate through a series of sequential said unit dose periods.
18. The method of claim 17 , wherein said unit dose periods are selected at least in part to reduce battery consumption.
19. The method of claim 17 , wherein said unit dose periods are selected so that an open/close rate of said valve is pharmacologically insignificant.
20. The method of claim 16 , further comprising:
providing an alert with respect to overfilling of said reservoir using said pressure differential across said flow restrictor.
21-34. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/021,967 US20080125702A1 (en) | 2001-03-01 | 2008-01-29 | Non-constant pressure infusion pump |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/796,969 US6620151B2 (en) | 2001-03-01 | 2001-03-01 | Non-constant pressure infusion pump |
US10/626,902 US7338464B2 (en) | 2001-03-01 | 2003-07-25 | Non-constant pressure infusion pump |
US12/021,967 US20080125702A1 (en) | 2001-03-01 | 2008-01-29 | Non-constant pressure infusion pump |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/626,902 Continuation US7338464B2 (en) | 2001-03-01 | 2003-07-25 | Non-constant pressure infusion pump |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080125702A1 true US20080125702A1 (en) | 2008-05-29 |
Family
ID=25169533
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/796,969 Expired - Lifetime US6620151B2 (en) | 2001-03-01 | 2001-03-01 | Non-constant pressure infusion pump |
US10/626,902 Expired - Fee Related US7338464B2 (en) | 2001-03-01 | 2003-07-25 | Non-constant pressure infusion pump |
US12/021,967 Abandoned US20080125702A1 (en) | 2001-03-01 | 2008-01-29 | Non-constant pressure infusion pump |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/796,969 Expired - Lifetime US6620151B2 (en) | 2001-03-01 | 2001-03-01 | Non-constant pressure infusion pump |
US10/626,902 Expired - Fee Related US7338464B2 (en) | 2001-03-01 | 2003-07-25 | Non-constant pressure infusion pump |
Country Status (6)
Country | Link |
---|---|
US (3) | US6620151B2 (en) |
EP (1) | EP1368079A1 (en) |
AU (1) | AU2002236842B2 (en) |
IL (1) | IL157685A0 (en) |
MX (1) | MXPA02002198A (en) |
WO (1) | WO2002070047A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110144540A1 (en) * | 2009-12-11 | 2011-06-16 | Medtronic, Inc. | Monitoring conditions of implantable medical fluid delivery device |
US20110254686A1 (en) * | 2010-04-16 | 2011-10-20 | Medtronic, Inc. | Reservoir monitoring for implantable fluid delivery devices |
US20130178792A1 (en) * | 2011-11-18 | 2013-07-11 | Minipumps, Llc. | Accurate flow control in drug pump devices |
US8568389B2 (en) | 2011-04-13 | 2013-10-29 | Medtronic, Inc. | Estimating the volume of fluid in therapeutic fluid delivery device reservoir |
US9199035B2 (en) | 2008-05-08 | 2015-12-01 | Minipumps, Llc. | Drug-delivery pumps with dynamic, adaptive control |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
US9623174B2 (en) | 2008-05-08 | 2017-04-18 | Minipumps, Llc | Implantable pumps and cannulas therefor |
US9687603B2 (en) | 2010-04-16 | 2017-06-27 | Medtronic, Inc. | Volume monitoring for implantable fluid delivery devices |
Families Citing this family (259)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7890176B2 (en) * | 1998-07-06 | 2011-02-15 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating chronic pelvic pain |
US6582441B1 (en) | 2000-02-24 | 2003-06-24 | Advanced Bionics Corporation | Surgical insertion tool |
US6620151B2 (en) * | 2001-03-01 | 2003-09-16 | Advanced Neuromodulation Systems, Inc. | Non-constant pressure infusion pump |
US7291126B2 (en) * | 2001-11-26 | 2007-11-06 | Nilimedix Ltd. | Drug delivery device and method |
EP1476209B1 (en) * | 2002-02-18 | 2008-07-30 | Danfoss A/S | Device for administering of medication in fluid form |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US8150520B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods for catheter-based renal denervation |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US7998062B2 (en) | 2004-03-29 | 2011-08-16 | Superdimension, Ltd. | Endoscope structures and techniques for navigating to a target in branched structure |
US7254449B2 (en) * | 2002-07-31 | 2007-08-07 | Advanced Bionics Corp | Systems and methods for providing power to one or more implantable devices |
IL154243A0 (en) * | 2003-02-02 | 2003-09-17 | Silex Projectors Ltd | Stable infusion device |
US8946151B2 (en) * | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
CA2523267C (en) | 2003-04-23 | 2013-09-03 | Biovalve Technologies, Inc. | Hydraulically actuated pump for long duration medicament administration |
US8021334B2 (en) | 2004-05-30 | 2011-09-20 | Nilimedix Ltd. | Drug delivery device and method |
CA2432810A1 (en) | 2003-06-19 | 2004-12-19 | Andres M. Lozano | Method of treating depression, mood disorders and anxiety disorders by brian infusion |
US8353857B2 (en) * | 2003-06-23 | 2013-01-15 | Codman & Shurtleff, Inc. | Implantable medical device having pressure sensors for diagnosing the performance of an implanted medical device |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
EP2316328B1 (en) | 2003-09-15 | 2012-05-09 | Super Dimension Ltd. | Wrap-around holding device for use with bronchoscopes |
US8396565B2 (en) | 2003-09-15 | 2013-03-12 | Medtronic, Inc. | Automatic therapy adjustments |
EP2113189B1 (en) | 2003-09-15 | 2013-09-04 | Covidien LP | System of accessories for use with bronchoscopes |
US7896865B2 (en) * | 2003-09-30 | 2011-03-01 | Codman & Shurtleff, Inc. | Two-compartment reduced volume infusion pump |
US9138537B2 (en) * | 2003-10-02 | 2015-09-22 | Medtronic, Inc. | Determining catheter status |
US9033920B2 (en) * | 2003-10-02 | 2015-05-19 | Medtronic, Inc. | Determining catheter status |
US7320676B2 (en) * | 2003-10-02 | 2008-01-22 | Medtronic, Inc. | Pressure sensing in implantable medical devices |
US8323244B2 (en) * | 2007-03-30 | 2012-12-04 | Medtronic, Inc. | Catheter malfunction determinations using physiologic pressure |
FR2860438B1 (en) * | 2003-10-07 | 2006-06-02 | Jean Marie Podvin | IMPLANTABLE PERFUSION DEVICE |
US8182461B2 (en) | 2003-11-04 | 2012-05-22 | Smiths Medical Asd, Inc. | Syringe pump rapid occlusion detection system |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US8532730B2 (en) | 2006-10-04 | 2013-09-10 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) * | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8425417B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
US8425416B2 (en) | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
US8364230B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
FR2864231B1 (en) * | 2003-12-19 | 2006-05-19 | Valois Sas | DEVICE FOR DISPENSING FLUID PRODUCT |
DE102004006453B4 (en) * | 2004-02-05 | 2007-03-29 | Ing. Erich Pfeiffer Gmbh | metering |
US8764725B2 (en) | 2004-02-09 | 2014-07-01 | Covidien Lp | Directional anchoring mechanism, method and applications thereof |
US20050187515A1 (en) * | 2004-02-19 | 2005-08-25 | Advanced Neuromodulation Systems, Inc. | Reduced size programmable drug pump |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
EP1750800A1 (en) * | 2004-04-30 | 2007-02-14 | Advanced Neuromodulation Systems, Inc. | Method of treating mood disorders and/or anxiety disorders by brain stimulation |
US20050267413A1 (en) * | 2004-05-26 | 2005-12-01 | Wang Jong H | Flow monitoring devices and methods of use |
US20050267555A1 (en) * | 2004-05-28 | 2005-12-01 | Marnfeldt Goran N | Engagement tool for implantable medical devices |
US7840268B2 (en) * | 2004-06-21 | 2010-11-23 | Advanced Neuromodulation Systems, Inc. | System and method of managing medical device historical data |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
WO2006010013A1 (en) * | 2004-07-09 | 2006-01-26 | Advanced Bionics Corporation | Systems and methods for using a butterfly coil to communicate with or transfer power to an implantable medical device |
US7946984B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
WO2006012423A1 (en) * | 2004-07-20 | 2006-02-02 | Medtronic, Inc. | Therapy programming guidance based on stored programming history |
US7819909B2 (en) * | 2004-07-20 | 2010-10-26 | Medtronic, Inc. | Therapy programming guidance based on stored programming history |
US8452407B2 (en) * | 2004-08-16 | 2013-05-28 | Boston Scientific Neuromodulation Corporation | Methods for treating gastrointestinal disorders |
US8214047B2 (en) * | 2004-09-27 | 2012-07-03 | Advanced Neuromodulation Systems, Inc. | Method of using spinal cord stimulation to treat gastrointestinal and/or eating disorders or conditions |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US9358393B1 (en) | 2004-11-09 | 2016-06-07 | Andres M. Lozano | Stimulation methods and systems for treating an auditory dysfunction |
US7483746B2 (en) * | 2004-12-06 | 2009-01-27 | Boston Scientific Neuromodulation Corp. | Stimulation of the stomach in response to sensed parameters to treat obesity |
WO2006067555A1 (en) * | 2004-12-21 | 2006-06-29 | Maquet Critical Care Ab | Liquid dosing arrangement |
US20060161217A1 (en) * | 2004-12-21 | 2006-07-20 | Jaax Kristen N | Methods and systems for treating obesity |
US9095713B2 (en) | 2004-12-21 | 2015-08-04 | Allison M. Foster | Methods and systems for treating autism by decreasing neural activity within the brain |
US20070038264A1 (en) * | 2004-12-21 | 2007-02-15 | Jaax Kristen N | Methods and systems for treating autism |
US9327069B2 (en) | 2004-12-21 | 2016-05-03 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating a medical condition by promoting neural remodeling within the brain |
US9352145B2 (en) | 2004-12-22 | 2016-05-31 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating a psychotic disorder |
US8515541B1 (en) | 2004-12-22 | 2013-08-20 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating post-stroke disorders |
US7628590B2 (en) * | 2005-02-16 | 2009-12-08 | Sterling Investments Lc | Method and apparatus for reducing free flow risk |
WO2006094072A2 (en) * | 2005-03-01 | 2006-09-08 | Functional Neuroscience Inc. | Method of treating cognitive disorders using neuromodulation |
CA2599959A1 (en) * | 2005-03-01 | 2006-09-08 | Functional Neuroscience Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
US20060200205A1 (en) * | 2005-03-01 | 2006-09-07 | Haller Matthew I | Systems and methods for treating a patient with multiple stimulation therapies |
US7853321B2 (en) * | 2005-03-14 | 2010-12-14 | Boston Scientific Neuromodulation Corporation | Stimulation of a stimulation site within the neck or head |
US7702385B2 (en) * | 2005-11-16 | 2010-04-20 | Boston Scientific Neuromodulation Corporation | Electrode contact configurations for an implantable stimulator |
US7848803B1 (en) | 2005-03-14 | 2010-12-07 | Boston Scientific Neuromodulation Corporation | Methods and systems for facilitating stimulation of one or more stimulation sites |
US8423155B1 (en) | 2005-03-14 | 2013-04-16 | Boston Scientific Neuromodulation Corporation | Methods and systems for facilitating stimulation of one or more stimulation sites |
US7627383B2 (en) * | 2005-03-15 | 2009-12-01 | Boston Scientific Neuromodulation Corporation | Implantable stimulator |
US8114055B2 (en) | 2005-05-10 | 2012-02-14 | Palyon Medical (Bvi) Limited | Implantable pump with infinitely variable resistor |
US8211060B2 (en) | 2005-05-10 | 2012-07-03 | Palyon Medical (Bvi) Limited | Reduced size implantable pump |
US8915893B2 (en) | 2005-05-10 | 2014-12-23 | Palyon Medical (Bvi) Limited | Variable flow infusion pump system |
US7637892B2 (en) * | 2005-05-10 | 2009-12-29 | Palyon Medical (Bvi) Limited | Variable flow infusion pump system |
US7200504B1 (en) | 2005-05-16 | 2007-04-03 | Advanced Bionics Corporation | Measuring temperature change in an electronic biomedical implant |
US20060276744A1 (en) * | 2005-05-20 | 2006-12-07 | Falk Theodore J | Configuration for drug delivery systems |
US8034030B2 (en) * | 2005-05-25 | 2011-10-11 | Palyon Medical (Bvi) Limited | Multi-reservoir implantable pump with variable flow rate capabilities |
DE102005050142B3 (en) * | 2005-10-19 | 2007-07-05 | Up Management Gmbh & Co Med-Systems Kg | Device for measuring the duration of injection |
US7729758B2 (en) | 2005-11-30 | 2010-06-01 | Boston Scientific Neuromodulation Corporation | Magnetically coupled microstimulators |
US7853322B2 (en) * | 2005-12-02 | 2010-12-14 | Medtronic, Inc. | Closed-loop therapy adjustment |
WO2007064924A1 (en) * | 2005-12-02 | 2007-06-07 | Medtronic, Inc. | Closed-loop therapy adjustment |
US7957809B2 (en) * | 2005-12-02 | 2011-06-07 | Medtronic, Inc. | Closed-loop therapy adjustment |
US7610100B2 (en) * | 2005-12-30 | 2009-10-27 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating osteoarthritis |
US7708730B2 (en) * | 2006-01-30 | 2010-05-04 | Palyon Medical (Bvi) Limited | Template system for multi-reservoir implantable pump |
US10010686B2 (en) * | 2006-02-27 | 2018-07-03 | Ivenix, Inc. | Fluid control system and disposable assembly |
US7777641B2 (en) * | 2006-03-29 | 2010-08-17 | Advanced Bionics, Llc | Systems and methods of facilitating communication between a first and second device |
CN103239773B (en) | 2006-03-30 | 2015-08-26 | 瓦莱里塔斯公司 | Multi-cartridge fluid delivery device |
EP2030643A1 (en) * | 2006-04-06 | 2009-03-04 | Medtronic, Inc. | Systems and methods for identifying catheter malfunctions using pressure sensing |
US8221354B2 (en) * | 2006-04-27 | 2012-07-17 | Medtronic, Inc. | Infusion device with positive pressure elastic bladder reservoir |
US20090108066A1 (en) * | 2006-06-14 | 2009-04-30 | Riotec Co., Ltd. | Optical system for barcode scanner |
US8504163B1 (en) | 2006-06-30 | 2013-08-06 | Boston Scientific Neuromodulation Corporation | Cranially mounted stimulation systems and methods |
US8401654B1 (en) | 2006-06-30 | 2013-03-19 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating one or more effects of deafferentation |
US7937152B1 (en) | 2006-08-30 | 2011-05-03 | Functional Neuroscience, Inc. | Systems and methods for treating pain using brain stimulation |
CA2872297C (en) | 2006-09-28 | 2016-10-11 | Smith & Nephew, Inc. | Portable wound therapy system |
US7445528B1 (en) | 2006-09-29 | 2008-11-04 | Boston Scientific Neuromodulation Corporation | Connector assemblies |
US8447376B2 (en) | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
US8449464B2 (en) | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
US8562528B2 (en) | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
US8298142B2 (en) | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
US8275438B2 (en) | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
ES2564519T3 (en) | 2006-10-13 | 2016-03-23 | Bluesky Medical Group Inc. | Pressure control of a medical vacuum pump |
US7347746B1 (en) | 2006-10-27 | 2008-03-25 | Boston Scientific Neuromodulation Corporation | Receptacle connector assembly |
US8280514B2 (en) * | 2006-10-31 | 2012-10-02 | Advanced Neuromodulation Systems, Inc. | Identifying areas of the brain by examining the neuronal signals |
US8167832B2 (en) * | 2006-12-09 | 2012-05-01 | The Alfred E. Mann Foundation For Scientific Research | Ambulatory infusion devices and methods including occlusion monitoring |
WO2009081262A1 (en) | 2007-12-18 | 2009-07-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
KR20090128499A (en) | 2007-03-19 | 2009-12-15 | 인슐린 메디컬 엘티디 | Drug delivery device |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
US9044537B2 (en) | 2007-03-30 | 2015-06-02 | Medtronic, Inc. | Devices and methods for detecting catheter complications |
US7892213B2 (en) * | 2007-04-20 | 2011-02-22 | Carefusion 303, Inc. | Fluid flow control system having capillary fluid flow restrictor |
WO2008154312A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
GB0715211D0 (en) * | 2007-08-06 | 2007-09-12 | Smith & Nephew | Apparatus |
GB0715259D0 (en) | 2007-08-06 | 2007-09-12 | Smith & Nephew | Canister status determination |
US9408954B2 (en) | 2007-07-02 | 2016-08-09 | Smith & Nephew Plc | Systems and methods for controlling operation of negative pressure wound therapy apparatus |
GB0712763D0 (en) | 2007-07-02 | 2007-08-08 | Smith & Nephew | Apparatus |
CN101951987B (en) * | 2007-09-17 | 2015-03-18 | 萨蒂什·桑达尔 | High precision infusion pump controller |
US8905920B2 (en) | 2007-09-27 | 2014-12-09 | Covidien Lp | Bronchoscope adapter and method |
US20090093774A1 (en) * | 2007-10-04 | 2009-04-09 | Baxter International Inc. | Ambulatory pump with intelligent flow control |
US8215157B2 (en) * | 2007-10-04 | 2012-07-10 | Baxter International Inc. | System and method for measuring liquid viscosity in a fluid delivery system |
US9452258B2 (en) | 2007-10-09 | 2016-09-27 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
DE102007048880B4 (en) * | 2007-10-11 | 2009-07-30 | Up Management Gmbh | A sphygmomanometer and method of operating a sphygmomanometer |
DE102007049446A1 (en) | 2007-10-16 | 2009-04-23 | Cequr Aps | Catheter introducer |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
EP2227769A2 (en) * | 2007-11-28 | 2010-09-15 | Medtronic, Inc. | Method and apparatus for multi-input stepwise infusion prescription with sensor data |
WO2009073891A1 (en) * | 2007-12-07 | 2009-06-11 | Northstar Neuroscience, Inc. | Systems and methods for providing targeted neural stimulation therapy to address neurological disorders, including neuropyschiatric and neuropyschological disorders |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
WO2009105709A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
GB0803564D0 (en) | 2008-02-27 | 2008-04-02 | Smith & Nephew | Fluid collection |
US7867192B2 (en) * | 2008-02-29 | 2011-01-11 | The Alfred E. Mann Foundation For Scientific Research | Ambulatory infusion devices and methods with blockage detection |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
WO2009122273A2 (en) | 2008-04-03 | 2009-10-08 | Superdimension, Ltd. | Magnetic interference detection system and method |
US8702637B2 (en) | 2008-04-14 | 2014-04-22 | Haemonetics Corporation | System and method for optimized apheresis draw and return |
US20090270844A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Flow sensor controlled infusion device |
US10912869B2 (en) | 2008-05-21 | 2021-02-09 | Smith & Nephew, Inc. | Wound therapy system with related methods therefor |
US8414519B2 (en) | 2008-05-21 | 2013-04-09 | Covidien Lp | Wound therapy system with portable container apparatus |
US8177763B2 (en) | 2008-09-05 | 2012-05-15 | Tyco Healthcare Group Lp | Canister membrane for wound therapy system |
EP2297673B1 (en) | 2008-06-03 | 2020-04-22 | Covidien LP | Feature-based registration method |
US8218847B2 (en) | 2008-06-06 | 2012-07-10 | Superdimension, Ltd. | Hybrid registration method |
US8932207B2 (en) | 2008-07-10 | 2015-01-13 | Covidien Lp | Integrated multi-functional endoscopic tool |
US8209028B2 (en) | 2008-07-11 | 2012-06-26 | Medtronic, Inc. | Objectification of posture state-responsive therapy based on patient therapy adjustments |
US9440084B2 (en) | 2008-07-11 | 2016-09-13 | Medtronic, Inc. | Programming posture responsive therapy |
US8504150B2 (en) | 2008-07-11 | 2013-08-06 | Medtronic, Inc. | Associating therapy adjustments with posture states using a stability timer |
US8437861B2 (en) | 2008-07-11 | 2013-05-07 | Medtronic, Inc. | Posture state redefinition based on posture data and therapy adjustments |
US8583252B2 (en) | 2008-07-11 | 2013-11-12 | Medtronic, Inc. | Patient interaction with posture-responsive therapy |
US8326420B2 (en) | 2008-07-11 | 2012-12-04 | Medtronic, Inc. | Associating therapy adjustments with posture states using stability timers |
US8708934B2 (en) | 2008-07-11 | 2014-04-29 | Medtronic, Inc. | Reorientation of patient posture states for posture-responsive therapy |
US9050471B2 (en) | 2008-07-11 | 2015-06-09 | Medtronic, Inc. | Posture state display on medical device user interface |
US9776008B2 (en) | 2008-07-11 | 2017-10-03 | Medtronic, Inc. | Posture state responsive therapy delivery using dwell times |
US8827983B2 (en) | 2008-08-21 | 2014-09-09 | Smith & Nephew, Inc. | Sensor with electrical contact protection for use in fluid collection canister and negative pressure wound therapy systems including same |
EP2158930B1 (en) * | 2008-08-27 | 2017-06-28 | F. Hoffmann-La Roche AG | Flow control valves for leakage detection, free-flow prevention and occlusion detection |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
US8280517B2 (en) | 2008-09-19 | 2012-10-02 | Medtronic, Inc. | Automatic validation techniques for validating operation of medical devices |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
US8105269B2 (en) | 2008-10-24 | 2012-01-31 | Baxter International Inc. | In situ tubing measurements for infusion pumps |
CN102245137A (en) | 2008-11-07 | 2011-11-16 | 茵苏莱恩医药有限公司 | Device and method for drug delivery |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8137083B2 (en) | 2009-03-11 | 2012-03-20 | Baxter International Inc. | Infusion pump actuators, system and method for controlling medical fluid flowrate |
US8611984B2 (en) | 2009-04-08 | 2013-12-17 | Covidien Lp | Locatable catheter |
US9026223B2 (en) | 2009-04-30 | 2015-05-05 | Medtronic, Inc. | Therapy system including multiple posture sensors |
US9327070B2 (en) | 2009-04-30 | 2016-05-03 | Medtronic, Inc. | Medical device therapy based on posture and timing |
US8175720B2 (en) | 2009-04-30 | 2012-05-08 | Medtronic, Inc. | Posture-responsive therapy control based on patient input |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US8672873B2 (en) | 2009-08-18 | 2014-03-18 | Cequr Sa | Medicine delivery device having detachable pressure sensing unit |
US8547239B2 (en) | 2009-08-18 | 2013-10-01 | Cequr Sa | Methods for detecting failure states in a medicine delivery device |
CA2793835C (en) | 2009-10-21 | 2021-07-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
US8382447B2 (en) | 2009-12-31 | 2013-02-26 | Baxter International, Inc. | Shuttle pump with controlled geometry |
US8579834B2 (en) | 2010-01-08 | 2013-11-12 | Medtronic, Inc. | Display of detected patient posture state |
US8388555B2 (en) | 2010-01-08 | 2013-03-05 | Medtronic, Inc. | Posture state classification for a medical device |
US9956418B2 (en) | 2010-01-08 | 2018-05-01 | Medtronic, Inc. | Graphical manipulation of posture zones for posture-responsive therapy |
US9357949B2 (en) | 2010-01-08 | 2016-06-07 | Medtronic, Inc. | User interface that displays medical therapy and posture data |
CN102892458A (en) * | 2010-03-04 | 2013-01-23 | 亭阁控股有限责任公司 | Systems and methods for infusion of fluids using stored potential energy and variable flow resistor |
US8612055B2 (en) | 2010-04-16 | 2013-12-17 | Medtronic, Inc. | System and method for delivering a therapeutic agent according to default infusion schedule |
US9566441B2 (en) | 2010-04-30 | 2017-02-14 | Medtronic, Inc. | Detecting posture sensor signal shift or drift in medical devices |
US8397578B2 (en) | 2010-06-03 | 2013-03-19 | Medtronic, Inc. | Capacitive pressure sensor assembly |
US9737657B2 (en) | 2010-06-03 | 2017-08-22 | Medtronic, Inc. | Implantable medical pump with pressure sensor |
WO2011159834A1 (en) | 2010-06-15 | 2011-12-22 | Superdimension, Ltd. | Locatable expandable working channel and method |
US8567235B2 (en) | 2010-06-29 | 2013-10-29 | Baxter International Inc. | Tube measurement technique using linear actuator and pressure sensor |
US8876756B2 (en) * | 2010-08-11 | 2014-11-04 | Ivenix, Inc. | Portable infusion management apparatus and method |
JP2012066004A (en) * | 2010-09-27 | 2012-04-05 | Ricoh Co Ltd | Solution sending system, solution sending method and program |
US9211378B2 (en) | 2010-10-22 | 2015-12-15 | Cequr Sa | Methods and systems for dosing a medicament |
EP3449856B1 (en) | 2010-10-25 | 2023-06-28 | Medtronic Ardian Luxembourg S.à.r.l. | Device for evaluation and feedback of neuromodulation treatment |
US20120191074A1 (en) * | 2011-01-21 | 2012-07-26 | Palyon Medical (Bvi) Limited | Reduced sized programmable pump |
DK3575796T3 (en) | 2011-04-15 | 2021-01-18 | Dexcom Inc | ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION |
US9940440B2 (en) | 2011-04-28 | 2018-04-10 | Medtronic, Inc. | Detecting and responding to software and hardware anomalies in a fluid delivery system |
US9872956B2 (en) | 2011-04-29 | 2018-01-23 | Medtronic, Inc. | Limiting pressure in an implanted catheter |
US20130037142A1 (en) * | 2011-08-08 | 2013-02-14 | Fresenius Medical Care Holdings, Inc. | Dialysis system having peristaltic pump arrangement |
US8568360B2 (en) | 2011-12-28 | 2013-10-29 | Palyon Medical (Bvi) Limited | Programmable implantable pump design |
US8591456B2 (en) | 2011-12-28 | 2013-11-26 | Palyon Medical (Bvi) Limited | Multiple reservoir programmable pump |
US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
WO2013134733A2 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Biomarker sampling in the context of neuromodulation devices and associated systems and methods |
US9907959B2 (en) | 2012-04-12 | 2018-03-06 | Medtronic, Inc. | Velocity detection for posture-responsive therapy |
US9737719B2 (en) | 2012-04-26 | 2017-08-22 | Medtronic, Inc. | Adjustment of therapy based on acceleration |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
US9056166B2 (en) | 2013-01-21 | 2015-06-16 | Baxter International Inc. | Infusion pump and method to enhance long term medication delivery accuracy |
US20140276557A1 (en) * | 2013-03-13 | 2014-09-18 | Palyon Medical Corporation | Dual rate insulin pump |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9421329B2 (en) | 2013-03-15 | 2016-08-23 | Tandem Diabetes Care, Inc. | Infusion device occlusion detection system |
US9180243B2 (en) | 2013-03-15 | 2015-11-10 | Tandem Diabetes Care, Inc. | Detection of infusion pump conditions |
US9610444B2 (en) | 2013-03-15 | 2017-04-04 | Pacesetter, Inc. | Erythropoeitin production by electrical stimulation |
US9603995B2 (en) | 2013-03-15 | 2017-03-28 | Tandem Diabetes Care. Inc. | Device and method for setting therapeutic parameters for an infusion device |
US20150182698A1 (en) | 2013-12-31 | 2015-07-02 | Abbvie Inc. | Pump, motor and assembly for beneficial agent delivery |
WO2015114534A1 (en) * | 2014-01-28 | 2015-08-06 | Debiotech S.A. | Control device with recommendations |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10952593B2 (en) | 2014-06-10 | 2021-03-23 | Covidien Lp | Bronchoscope adapter |
JP6644764B2 (en) | 2014-07-31 | 2020-02-12 | スミス アンド ネフュー インコーポレイテッド | Systems and methods for delivering decompression therapy |
US10426555B2 (en) | 2015-06-03 | 2019-10-01 | Covidien Lp | Medical instrument with sensor for use in a system and method for electromagnetic navigation |
EP3346913A4 (en) | 2015-09-25 | 2019-01-16 | C.R. Bard Inc. | Catheter assembly including monitoring capabilities |
JP6761034B2 (en) * | 2015-10-21 | 2020-09-23 | エドワーズ ライフサイエンシーズ コーポレイションEdwards Lifesciences Corporation | Injection measurement and control by thermal dilution method |
CN108778371B (en) | 2016-01-20 | 2020-08-07 | 梅戴林治疗公司 | Ambulatory infusion device and related methods |
US10478254B2 (en) | 2016-05-16 | 2019-11-19 | Covidien Lp | System and method to access lung tissue |
US10517505B2 (en) | 2016-10-28 | 2019-12-31 | Covidien Lp | Systems, methods, and computer-readable media for optimizing an electromagnetic navigation system |
US10418705B2 (en) | 2016-10-28 | 2019-09-17 | Covidien Lp | Electromagnetic navigation antenna assembly and electromagnetic navigation system including the same |
US10615500B2 (en) | 2016-10-28 | 2020-04-07 | Covidien Lp | System and method for designing electromagnetic navigation antenna assemblies |
US10792106B2 (en) | 2016-10-28 | 2020-10-06 | Covidien Lp | System for calibrating an electromagnetic navigation system |
US10446931B2 (en) | 2016-10-28 | 2019-10-15 | Covidien Lp | Electromagnetic navigation antenna assembly and electromagnetic navigation system including the same |
US10638952B2 (en) | 2016-10-28 | 2020-05-05 | Covidien Lp | Methods, systems, and computer-readable media for calibrating an electromagnetic navigation system |
US10722311B2 (en) | 2016-10-28 | 2020-07-28 | Covidien Lp | System and method for identifying a location and/or an orientation of an electromagnetic sensor based on a map |
US10751126B2 (en) | 2016-10-28 | 2020-08-25 | Covidien Lp | System and method for generating a map for electromagnetic navigation |
CN110267697B (en) | 2017-02-10 | 2022-04-29 | 巴克斯特国际公司 | Volume-based flow compensation techniques for infusion therapy |
US11471571B2 (en) | 2017-04-19 | 2022-10-18 | Smith & Nephew, Inc. | Negative pressure wound therapy canisters |
US20190120785A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11219489B2 (en) | 2017-10-31 | 2022-01-11 | Covidien Lp | Devices and systems for providing sensors in parallel with medical tools |
WO2019158997A1 (en) * | 2018-02-16 | 2019-08-22 | Cequr Sa | Devices and methods for flow restriction in a microfluidic circuit for drug delivery |
CA3134668A1 (en) | 2019-04-10 | 2020-10-15 | PAVmed Inc. | Systems and methods for a variable flow resistor |
CN112957563B (en) * | 2021-03-18 | 2022-09-06 | 台州恩泽医疗中心(集团) | Micro-injection pump for ICU department |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3731681A (en) * | 1970-05-18 | 1973-05-08 | Univ Minnesota | Implantable indusion pump |
US3946731A (en) * | 1971-01-20 | 1976-03-30 | Lichtenstein Eric Stefan | Apparatus for extracorporeal treatment of blood |
US3951147A (en) * | 1975-04-07 | 1976-04-20 | Metal Bellows Company | Implantable infusate pump |
US4077405A (en) * | 1975-03-26 | 1978-03-07 | Siemens Aktiengesellschaft | Apparatus for infusing liquids into human or animal bodies |
US4299220A (en) * | 1979-05-03 | 1981-11-10 | The Regents Of The University Of Minnesota | Implantable drug infusion regulator |
US4370983A (en) * | 1971-01-20 | 1983-02-01 | Lichtenstein Eric Stefan | Computer-control medical care system |
US4443218A (en) * | 1982-09-09 | 1984-04-17 | Infusaid Corporation | Programmable implantable infusate pump |
US4772263A (en) * | 1986-02-03 | 1988-09-20 | Regents Of The University Of Minnesota | Spring driven infusion pump |
US4836752A (en) * | 1987-11-02 | 1989-06-06 | Fisher Scientific Company | Partial restriction detector |
US4838887A (en) * | 1987-12-15 | 1989-06-13 | Shiley Infusaid Inc. | Programmable valve pump |
US4978338A (en) * | 1988-04-21 | 1990-12-18 | Therex Corp. | Implantable infusion apparatus |
US5006997A (en) * | 1987-12-15 | 1991-04-09 | Shiley Infusaid, Inc. | Pump diagnostic system |
US5224843A (en) * | 1989-06-14 | 1993-07-06 | Westonbridge International Ltd. | Two valve micropump with improved outlet |
US5342404A (en) * | 1992-04-03 | 1994-08-30 | Intermedics, Inc. | Implantable medical interventional device |
US5993414A (en) * | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
US6129702A (en) * | 1996-12-03 | 2000-10-10 | Fraunhofer-Gesellschaft Zur Forderung Angewandten Forschung E.V. | Medicament dosing system |
US6488652B1 (en) * | 1998-02-02 | 2002-12-03 | Medtronic, Inc. | Safety valve assembly for implantable benefical agent infusion device |
US6572583B1 (en) * | 2000-04-28 | 2003-06-03 | Medtronic, Inc. | Bulkhead for implantable infusion device |
US6589205B1 (en) * | 1999-12-17 | 2003-07-08 | Advanced Bionica Corporation | Externally-controllable constant-flow medication delivery system |
US6635014B2 (en) * | 2000-01-21 | 2003-10-21 | Timothy J. Starkweather | Ambulatory medical apparatus and method having telemetry modifiable control software |
US20040153029A1 (en) * | 2001-03-01 | 2004-08-05 | Advanced Neuromodulation Systems, Inc. | Non-constant pressure infusion pump |
US6986753B2 (en) * | 1998-05-21 | 2006-01-17 | Buivision | Constant ocular pressure active infusion system |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1154345A (en) | 1980-03-07 | 1983-09-27 | Elton M. Tucker | Controlled infusion apparatus and method |
CH644568A5 (en) * | 1980-07-11 | 1984-08-15 | Bertrams Ag | METHOD AND DEVICE FOR CONCENTRATING ALKALI LYE. |
DE3520782A1 (en) | 1985-06-10 | 1986-12-11 | Siemens AG, 1000 Berlin und 8000 München | Medicament metering device with reservoir and metering store |
US5061242A (en) | 1989-07-18 | 1991-10-29 | Infusaid, Inc. | Adjustable implantable drug infusion system |
US5067943A (en) | 1989-09-26 | 1991-11-26 | Infusaid, Inc. | Pressure regulator for implantable pump |
US6579280B1 (en) | 1999-04-30 | 2003-06-17 | Medtronic, Inc. | Generic multi-step therapeutic treatment protocol |
-
2001
- 2001-03-01 US US09/796,969 patent/US6620151B2/en not_active Expired - Lifetime
-
2002
- 2002-01-24 EP EP02703208A patent/EP1368079A1/en not_active Withdrawn
- 2002-01-24 IL IL15768502A patent/IL157685A0/en unknown
- 2002-01-24 AU AU2002236842A patent/AU2002236842B2/en not_active Ceased
- 2002-01-24 WO PCT/US2002/001912 patent/WO2002070047A1/en not_active Application Discontinuation
- 2002-02-28 MX MXPA02002198A patent/MXPA02002198A/en unknown
-
2003
- 2003-07-25 US US10/626,902 patent/US7338464B2/en not_active Expired - Fee Related
-
2008
- 2008-01-29 US US12/021,967 patent/US20080125702A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3731681A (en) * | 1970-05-18 | 1973-05-08 | Univ Minnesota | Implantable indusion pump |
US3946731A (en) * | 1971-01-20 | 1976-03-30 | Lichtenstein Eric Stefan | Apparatus for extracorporeal treatment of blood |
US4370983A (en) * | 1971-01-20 | 1983-02-01 | Lichtenstein Eric Stefan | Computer-control medical care system |
US4077405A (en) * | 1975-03-26 | 1978-03-07 | Siemens Aktiengesellschaft | Apparatus for infusing liquids into human or animal bodies |
US3951147A (en) * | 1975-04-07 | 1976-04-20 | Metal Bellows Company | Implantable infusate pump |
US4299220A (en) * | 1979-05-03 | 1981-11-10 | The Regents Of The University Of Minnesota | Implantable drug infusion regulator |
US4443218A (en) * | 1982-09-09 | 1984-04-17 | Infusaid Corporation | Programmable implantable infusate pump |
US4772263A (en) * | 1986-02-03 | 1988-09-20 | Regents Of The University Of Minnesota | Spring driven infusion pump |
US4836752A (en) * | 1987-11-02 | 1989-06-06 | Fisher Scientific Company | Partial restriction detector |
US5006997A (en) * | 1987-12-15 | 1991-04-09 | Shiley Infusaid, Inc. | Pump diagnostic system |
US4838887A (en) * | 1987-12-15 | 1989-06-13 | Shiley Infusaid Inc. | Programmable valve pump |
US4978338A (en) * | 1988-04-21 | 1990-12-18 | Therex Corp. | Implantable infusion apparatus |
US5224843A (en) * | 1989-06-14 | 1993-07-06 | Westonbridge International Ltd. | Two valve micropump with improved outlet |
US5342404A (en) * | 1992-04-03 | 1994-08-30 | Intermedics, Inc. | Implantable medical interventional device |
US6129702A (en) * | 1996-12-03 | 2000-10-10 | Fraunhofer-Gesellschaft Zur Forderung Angewandten Forschung E.V. | Medicament dosing system |
US6488652B1 (en) * | 1998-02-02 | 2002-12-03 | Medtronic, Inc. | Safety valve assembly for implantable benefical agent infusion device |
US5993414A (en) * | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
US6986753B2 (en) * | 1998-05-21 | 2006-01-17 | Buivision | Constant ocular pressure active infusion system |
US6589205B1 (en) * | 1999-12-17 | 2003-07-08 | Advanced Bionica Corporation | Externally-controllable constant-flow medication delivery system |
US6635014B2 (en) * | 2000-01-21 | 2003-10-21 | Timothy J. Starkweather | Ambulatory medical apparatus and method having telemetry modifiable control software |
US6572583B1 (en) * | 2000-04-28 | 2003-06-03 | Medtronic, Inc. | Bulkhead for implantable infusion device |
US20040153029A1 (en) * | 2001-03-01 | 2004-08-05 | Advanced Neuromodulation Systems, Inc. | Non-constant pressure infusion pump |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9199035B2 (en) | 2008-05-08 | 2015-12-01 | Minipumps, Llc. | Drug-delivery pumps with dynamic, adaptive control |
US9623174B2 (en) | 2008-05-08 | 2017-04-18 | Minipumps, Llc | Implantable pumps and cannulas therefor |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
US9849238B2 (en) | 2008-05-08 | 2017-12-26 | Minipumps, Llc | Drug-delivery pump with intelligent control |
US9283322B2 (en) | 2008-05-08 | 2016-03-15 | Minipumps, Llc | Drug-delivery pump with dynamic, adaptive control |
US20110144540A1 (en) * | 2009-12-11 | 2011-06-16 | Medtronic, Inc. | Monitoring conditions of implantable medical fluid delivery device |
US9901679B2 (en) | 2009-12-11 | 2018-02-27 | Medtronic, Inc. | Monitoring conditions of an implantable medical fluid delivery device |
US8998841B2 (en) * | 2009-12-11 | 2015-04-07 | Medtronic, Inc. | Monitoring conditions of implantable medical fluid delivery device |
US8810394B2 (en) * | 2010-04-16 | 2014-08-19 | Medtronic, Inc. | Reservoir monitoring for implantable fluid delivery devices |
EP2558146A1 (en) * | 2010-04-16 | 2013-02-20 | Medtronic, Inc. | Reservoir monitoring for implantable fluid delivery devices |
US20110254686A1 (en) * | 2010-04-16 | 2011-10-20 | Medtronic, Inc. | Reservoir monitoring for implantable fluid delivery devices |
US9687603B2 (en) | 2010-04-16 | 2017-06-27 | Medtronic, Inc. | Volume monitoring for implantable fluid delivery devices |
US8568389B2 (en) | 2011-04-13 | 2013-10-29 | Medtronic, Inc. | Estimating the volume of fluid in therapeutic fluid delivery device reservoir |
US20130178792A1 (en) * | 2011-11-18 | 2013-07-11 | Minipumps, Llc. | Accurate flow control in drug pump devices |
US8939930B2 (en) * | 2011-11-18 | 2015-01-27 | Minipumps, Llc | Accurate flow control in drug pump devices |
Also Published As
Publication number | Publication date |
---|---|
EP1368079A1 (en) | 2003-12-10 |
MXPA02002198A (en) | 2002-10-28 |
US20040153029A1 (en) | 2004-08-05 |
AU2002236842B2 (en) | 2006-09-14 |
US7338464B2 (en) | 2008-03-04 |
US6620151B2 (en) | 2003-09-16 |
IL157685A0 (en) | 2004-03-28 |
US20020156464A1 (en) | 2002-10-24 |
WO2002070047A1 (en) | 2002-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7338464B2 (en) | Non-constant pressure infusion pump | |
AU2002236842A1 (en) | Non-constant pressure infusion pump | |
CA1134232A (en) | Implantable infusion apparatus and method | |
US4714462A (en) | Positive pressure programmable infusion pump | |
US7867203B2 (en) | Implantable pump with adjustable flow rate | |
US4447224A (en) | Variable flow implantable infusion apparatus | |
US9283322B2 (en) | Drug-delivery pump with dynamic, adaptive control | |
EP2280750B1 (en) | Flow sensor controlled infusion device | |
US6629954B1 (en) | Drug delivery pump with isolated hydraulic metering | |
US8945052B2 (en) | Dual drug delivery device | |
US20100137842A1 (en) | Ambulatory Infusion Devices With Improved Delivery Accuracy | |
US20120053571A1 (en) | Fluid delivery device with active and passive fluid delivery | |
RU2308978C2 (en) | Infusion pump | |
CA1154345A (en) | Controlled infusion apparatus and method | |
US9259530B2 (en) | Implantable infusion device | |
US20220203025A1 (en) | Implantable medical device with drug reservoir volume measurement system | |
CN116603127A (en) | Implantable pump optionally generating pulsatile flow |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |